Natural Products as Aromatase Inhibitors
Abstract
With the clinical success of several synthetic aromatase inhibitors (AIs) in the treatment of postmenopausal estrogen receptor-positive breast cancer, researchers have also been investigating also the potential of natural products as AIs. Natural products from terrestrial and marine organisms provide a chemically diverse array of compounds not always available through current synthetic chemistry techniques. Natural products that have been used traditionally for nutritional or medicinal purposes (e.g., botanical dietary supplements) may also afford AIs with reduced side effects. A thorough review of the literature regarding natural product extracts and secondary metabolites of plant, microbial, and marine origin that have been shown to exhibit aromatase inhibitory activity is presented herein.
BREAST CANCER
Worldwide breast cancer estimates included over one million incident cases and almost 400,000 deaths in the year 2000 [1, 2]. In the United States, over 178,000 women were expected to be diagnosed with breast cancer in 2007 with over 40,000 deaths occurring from the disease [3]. In developed countries, mortality from breast cancer has recently begun to decline, primarily due to earlier detection and improved treatments [4, 5]. Breast cancer is thought to be a result of inherited genetic predisposition (e.g., mutations in genes such as BRCA-1, BRCA-2, p53, PTEN/MMAC1, and/or ATM) and/or environmental factors (e.g., radiation exposure, dietary factors, alcohol consumption, hormonal exposure) [2, 6, 7]. Numerous genetic mutations are necessary for breast cancer development and progression including the acquisition of the capabilities for self-sufficiency in growth signals, insensitivity to anti-growth signals, evasion of apoptosis, limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis, known collectively as the “hallmarks of cancer” [8].
Numerous molecular targets have been identified as playing a significant role in breast cancer development and progression. Estrogens and the estrogen receptors (ERs) are widely recognized to play an important role in the development and progression of breast cancer, making estrogens and the ERs widely studied molecular targets [9–12]. Two of the endogenous estrogens found in humans include estradiol and estrone. In pre-menopausal women, estrogens are produced primarily through conversion of androgens in the ovaries while estrogen production in postmenopausal women occurs in only peripheral tissues [13, 14]. Estrogens have various effects throughout the body, including positive effects on the brain, bone, heart, liver, and vagina, with negative effects such as increased risk of breast and uterine cancers with prolonged estrogen exposure [10, 15, 16]. Estrogens exhibit their effects through binding to one of two variants of ERs, ERα or ERβ [17, 18]. Upon binding of estrogen, the ER dimerizes and binds to the estrogen-response element (ERE), causing transcription of estrogen dependent genes [19]. Estrogens influence breast cancer development and progression by various methods including stimulation of cell proliferation through the ERα pathway, direct increases in rates of genetic mutations, or effects on the DNA repair system [12, 20–22].
Modulation of estrogen exposure as a treatment for breast cancer began as early as the late nineteenth century when complete ovariectomy was noticed to have favorable effects on cancerous progression [23]. While ovarian ablation (through surgery, irradiation, or medication) is still utilized clinically for some pre-menopausal breast cancer patients [19, 24], extensive research has been performed to modify estrogen exposure pharmacologically. Modulation of estrogens and ERs can be accomplished by inhibiting ER binding, by downregulating ERs, or by decreasing estrogen production [24–26]. Tamoxifen (Nolvadex®), a selective estrogen receptor modulator (SERM) that works by blocking the binding of estrogen to the ER, has been considered the treatment of choice for estrogen abatement for the last twenty-five years [27, 28]. However, tamoxifen acts as both an ER antagonist and agonist in various tissues and thus results in significant side-effects such as increased risk of endometrial cancer and thromboembolism [26]. This partial antagonist/agonist activity is also thought to lead to the development of drug resistance and eventual treatment failure for patients using tamoxifen [29, 30]. Other SERMs, including raloxifene (Evista®, approved in United States for osteoporosis), and toremifene (Fareston®, approved in the United States to treat breast cancer) are in development to overcome these side effects and still maintain efficacy in breast cancer treatment [31–33]. Fulvestrant (Faslodex®) is a clinically approved estrogen receptor down-regulator currently used as second-line therapy in the treatment of postmenopausal metastatic breast cancer [34, 35]. An important target to decrease estrogen production involves aromatase inhibition, which has found clinical utility in postmenopausal women with breast cancer.
AROMATASE INHIBITION AND BREAST CANCER
Aromatase is a cytochrome P450 enzyme and is responsible for catalyzing the biosynthesis of estrogens (estrone and estradiol) from androgens (androstenedione and testosterone) (Fig. 1) [36, 37]. The aromatase enzyme is encoded by the aromatase gene CYP19 for which the expression is regulated by tissue-specific promoters, implying that aromatase expression is regulated differently in various tissues [38–41]. Aromatase has been found in numerous tissues throughout the body including breast, skin, brain, adipose, muscle, and bone [36, 37, 42]. The concentration of estrogens has been shown to be as much as twenty-fold higher in breast cancer tissues than in the circulating plasma, suggesting locally increased aromatase expression for estrogen biosynthesis near or within the cancerous tissues [13, 43]. Inhibition of the aromatase enzyme has been shown to reduce estrogen production throughout the body to nearly undetectable levels and is proving to have significant affect on the development and progression of hormone-responsive breast cancers. As such, aromatase inhibitors (AIs) can be utilized as either anticancer agents or for cancer chemoprevention [44–47]. However, the use of AIs for cancer chemotherapy or chemoprevention is limited to postmenopausal women or premenopausal women who have undergone ovarian ablation.
Conversion of cholesterol to androstenedione and testosterone, followed by aromatase catalyzed conversion to estrone and estradiol, respectively.
Aromatase inhibitors can be classified as either steroidal or nonsteroidal. Steroidal AIs (also known as Type I inhibitors) include competitive inhibitors and irreversible inhibitors, which covalently bind aromatase, producing enzyme inactivation. Nonsteroidal AIs (Type II inhibitors) reversibly bind the enzyme through interaction of a heteroatom on the inhibitor with the aromatase heme iron [42, 48, 49]. AIs have been clinically available since the introduction of aminoglutethimide (1, AG) in the late 1970's (Fig. 2) [42, 50]. However, AG did not completely inhibit aromatase, resulting in decreased efficacy, nor did AG selectively inhibit aromatase, causing considerable side effects [50]. Second-generation AIs (Fig. 2) include formestane (5), which was administered through intramuscular injection [19], and vorozole, both having various limiting side-effects [51]. Three third-generation AIs are currently in clinical use, namely, anastrozole (2, Arimidex®), letrozole (3, Femara®), and exemestane (6, Aromasin®) (Fig. 2) [19, 42, 45, 46, 49, 52]. These agents have shown nearly complete estrogen suppression and are highly selective for aromatase.
Examples of first1, second2, and third3 generation AIs, including AIs currently in clinical trials4. All three third generation compounds are currently approved for clinical use.
When compared with currently existing breast cancer therapies, aromatase inhibitors generally exhibit significantly improved efficacy with fewer side effects [53–55]. Current studies on synthetic AIs generally focus on combination treatment [56–58], resistance mechanisms [59–64], and/or improving their safety profile by reducing side effects [55, 65–67].
Although synthetic AIs show a better side effect profile than tamoxifen, serious side effects still occur, generally related to estrogen deprivation [68–72]. Synthetic AIs may cause decreased bone mineral density, osteoporosis, and increases in musculoskeletal disorders [55, 65, 66, 73–75]. Synthetic AIs also can result in increased cardiovascular events as well as altering the lipid profiles of patients [67, 74, 76]. Synthetic AIs can also affect cognition, decreasing the protective effects of estrogens on memory loss with aging [40, 77]. Several quality of life side effects are also often seen with the use of synthetic AIs including diarrhea, vaginal dryness, diminished libido, and dyspareunia [54, 78, 79]. Some of the side effects of synthetic AIs can be partially alleviated using available therapies, including osteoporosis treatments and cholesterol-lowering medicines.
Even with the improved efficacy of AIs or other endocrine therapies, postmenopausal breast cancer patients eventually develop resistance to AIs causing relapse of the disease [59–64, 80]. Generally, resistance involves tumor regrowth after 12–18 months of treatment and stable disease. Several mechanisms are thought to be involved in resistance to synthetic AIs including circumventing normal cellular pathways, enhancing sensitivity to existing estrogens, and/or redistributing estrogen receptors to extra-nuclear sites [59–64]. Several clinical trials are currently exploring the use of combination therapies with synthetic AIs and other compounds [e.g., epidermal growth factor receptor (EGFR) inhibitor gefitinib, HER-2/neu inhibitor trastuzumab, estrogen receptor degrader fulvestrant, and selective estrogen receptor modulators toremifene and raloxifene], hoping to extend the length of stable disease and reduce resistance mechanisms to synthetic AIs.
Two new aromatase inhibitors and one dietary supplement are currently undergoing clinical trials as single agent AIs (http://www.clinicaltrials.gov/). Atamestane (7, Fig. 2) is currently in two phase III clinical trials, including a recently completed study of atamestane with toremifene as compared with letrozole for advanced breast cancer and a study of toremifene with or without atamestane versus letrozole in women with metastatic breast cancer. In preclinical experiments, atamestane with or without toremifene was found to have fewer side-effects than letrozole, with favorable effects on bone, serum, and uterine markers [81]. Testolactone (4, Teslac®, Fig. 2) is considered a first generation AI and is currently approved for use in the United States for treatment of advanced breast cancer [82]. The AI activity of testolactone is thought to be competitive and irreversible, similar to other steroidal AIs. Testolactone is undergoing clinical trials for conditions other than breast cancer, including the recently completed study for the treatment of LHRH (lutenizing hormone-releasing hormone) resistant precocious puberty in girls (phase II), another recently completed study for the treatment of boys with precocious puberty (phase II), and as part of an ongoing study of a three drug combination therapy for children with congenital adrenal hyperplasia (phase I) [83, 84]. Phase I clinical trials have begun on the botanical dietary supplement IH636 grape seed extract for the prevention of breast cancer in postmenopausal women who are at increased risk of developing breast cancer. The IH636 extract has a high concentration of proanthocyanidins and has been shown to inhibit aromatase using in vitro and in vivo models [85, 86].
Even with the growing number of clinically used AIs including anastrozole, letrozole, exemestane, and other compounds in development there remains a need for improved AIs, due to the development of resistance to AIs and because of the side-effects associated with currently utilized compounds. New aromatase inhibitors could offer increased clinical efficacy and less severe side-effects. Although still theoretical, selective aromatase modulators (SAMs) may be found based on the evidence for tissue-specific promoters of aromatase expression [19, 41, 50]. Transcriptional regulation of aromatase is performed by several tissue-specific promoters, with normal breast adipose tissue utilizing PI.4 (major), PI.3 (minor), and PII (minor) promoters [46, 87]. Promotors PI.3 and PII both direct aromatase expression in breast cancer tissues, while other tissues utilize various promoters to regulate aromatase expression (PI.1 – placenta; PI.4 – skin; PI.5 – fetal tissues; PI.6 – bone; PI.7 – vacular endothelial; PII – ovary and testis; PIf – brain) [46, 87–89]. This tissue-specific regulation of aromatase expression by different promoters provides a possible mechanism for inhibiting aromatase expression in breast cancer tissues while continuing aromatase expression in peripheral tissues. For example, if PI.3 and PII could be downregulated in breast cancer tissues then there may be some minor side-effects in the ovary or testes, and the adipose tissue but the common side-effects of current AIs on the bone, brain, and cardiovascular system may be alleviated. Several researchers have been examining upstream targets that specifically influence promoters important in aromatase expression in breast cancer (e.g., COX-2 enzyme inhibitors that decrease aromatase expression involving PII and PI.4 [87] and liver receptor homologue (LRH)-1 modulators that decrease PII activity [90]).
NATURAL PRODUCTS AS AROMATASE INHIBITORS
With the clinical success of several synthetic aromatase inhibitors (AIs) for the treatment of postmenopausal breast cancer, researchers have been investigating the potential of natural products as AIs. Natural products have a long history of medicinal use in both traditional and modern societies, and have been utilized as herbal remedies, purified compounds, and as starting materials for combinatorial chemistry. Terrestrial flora and fauna, marine organisms, bacteria, fungi, and other microbes, provide a chemically diverse array of compounds not available through current synthetic chemistry techniques [e.g., 91–100]. Natural products that have been used traditionally for nutritional or medicinal purposes (for example, botanical dietary supplements and ethnobotanically utilized species) may also provide AIs with reduced side effects. Reduced side effects may be the result of compounds within the natural product matrix that inhibit aromatase while other compounds within the matrix alleviate some of the side effects of estrogen deprivation (e.g., phytoestrogens). As such, natural product AIs may be important for the translation of AIs from their current clinical uses as chemotherapeutic agents to future clinical uses in breast cancer chemoprevention. New natural product AIs may be clinically useful for treating postmenopausal breast cancer and may also act as chemopreventive agents for preventing secondary recurrence of breast cancer.
Natural product AIs may also be important in the search for more potent AIs. Natural product compounds that significantly inhibit aromatase may be utilized to direct synthetic modification of natural product scaffolds to enhance aromatase inhibition. Furthermore, natural product AIs could also be used to explore regulation of aromatase through other pathways and receptors {e.g., modulation of liver receptor homologue-1 (LRH-1) an orphan receptor that regulates aromatase in adipose tissue, testis, and granulose cells as well as contribute to over-expression of aromatase in breast cancer patients [90, 101]}. Natural product AIs could also be useful in the search for selective aromatase modulators (SAMs). Although still theoretical, selective aromatase modulators (SAMs) may be found based on the evidence for tissue-specific promoters of aromatase expression [19, 41, 50, 102, 103]. New natural product AIs could offer increased clinical efficacy and decreased side effects. Finally, screening for new natural product aromatase inhibitors may provide improved leads for future drug development.
The next sections of this article will detail natural product AIs that have been reported in the literature up to January 2008, beginning with a description of natural product extracts tested followed by a review of natural product compounds that have been tested.
NATURAL PRODUCT EXTRACTS TESTED FOR AROMATASE INHIBITION
Numerous natural product extracts have been tested for their ability to inhibit aromatase. Extracts evaluated have been produced mainly from edible plants and edible fungi, but have also included botanical dietary supplements, spices, teas, coffee, cycads, cigarettes and tobacco, traditional indigenous medicines, wine, and beer. Preparation of natural product extracts has rarely followed a standardized extract preparation method and in some cases this information has not been included in literature reports. Aromatase inhibition assays have varied widely, with the most common being a noncellular tritiated water release assay using microsomes from different sources, most commonly from human placentas. Although less frequent, cellular and in vivo aromatase inhibition assays have been utilized to test natural product extracts. In some cases other assays may be utilized to test for aromatase inhibition. Some studies did not report the assay utilized to determine aromatase inhibition activity. Assay results are presented in numerous forms [e.g., % inhibition, percent control activity (PCA), units/100 g], thus complicating the comparison of levels of aromatase inhibition activity from one sample to another. For the purposes of this review, the most active extracts in the microsomal assay will be discussed followed by discussion of the results of cellular and in vivo studies.
The most active natural product extracts from testing in the microsomal aromatase inhibition assay, reported as % inhibition, comprise the ethyl acetate partition of Dioon spinulosum Dyer ex Eichl. [104], the ethyl acetate partition of Encephalartos ferox Bertol. f. [104], a 75% methanol reflux extract of Riedelia Meisn. sp. [105], a 75% methanol reflux extract of Viscum album L. [105], the methanol partition of Cycas rumphii Miq. [104], the methanol and ethyl acetate partitions of Cycas revoluta Thunb. [104], a 75% methanol reflux extract of Alpinia purpurata K. Schum. [105], and a 75% methanol reflux extract of Coccothrinax Sarg. sp. [105]. The natural product extracts that were most active in the microsomal aromatase inhibition assay reported as PCA included five red wine varieties (Vitis L. sp.) from various wineries, with the most active being Cabernet Sauvignon from Tanglewood (France) [86, 106, 107]. The hexane partition of the leaves of Brassaiopsis glomerulata (Blume) Regel (Araliaceae) was found to be active in microsomes [108]. The methanol and chloroform extracts of Garcinia mangostana L. (Clusiaceae) (mangosteen) were also strongly inhibitory against aromatase in microsomes [109].
When results were reported as μg/mL, the most active extracts in the microsomal assay included a water reflux extract of Euonymus alatus (Thunb.) Sielbold (“gui-jun woo” in Korean folk medicine), a dichloromethane partition of Isodon excisus Kudo var. coreanus [110], a water reflux extract of Scutellaria barbata D. Don [111], and a polyphenol-enhanced extract of green tea (Camellia sinensis Kuntze) [112]. Another study reported results in units/100 g wet weight (one unit was defined as the dose required for 50% inhibition) and found tea (C. sinensis), coffee (Coffea L. sp.), cocoa (Theobroma cacao L.), collards (Brassica oleracea L.), and tomato leaves (Lycopersicon esculentum Mill.) to strongly inhibit aromatase using a microsomal assay [113]. Interestingly, this study also reported that cigarette smoke (obtained using methylene chloride and aqueous traps) and tobacco leaves (70% ethanol extract; Nicotiana tabacum L.) also potently inhibited aromatase, as reported in cigarette equivalents [113].
The Euonymus alatus (Thunb.) Sielbold and Scutellaria barabata D. Don extracts mentioned above were subjected to further testing in both myometrial and leiomyonal cells with the extracts found to have stronger aromatase inhibition activity in leiomyonal cells [111]. Other active natural product extracts tested in cellular aromatase assays included xanthohumol-rich stout beer in choriocarcinoma-derived JAR cells [114], a water extract of grape seed extract (Vitis L. sp.) in MCF-7aro cells [85], a water reflux extract of white button mushrooms [Agaricus bisporus (J. Lange) Imbach] in MCF-7aro cells [115], red clover flowers (Trifolium pratense L.) in a MCF-7 cell dual assay for aromatase inhibition and estrogenicity [116], mangosteen (Garcinia mangostana L.) in SK-BR-3 cells [109], and Brassaiopsis glomerulata (Blume) Regel in SK-BR-3 cells [108]. The red clover flowers were found to inhibit aromatase at low concentrations and were also estrogenic at high concentrations.
One of the red wines [Pinot noir from Hacienda (Sonoma, CA); Vitis L. sp.] with demonstrated activity in the microsomal assay was further tested in vivo using an aromatase-transfected MCF-7 breast cancer xenograft mouse model and found to be active [86, 106, 107]. The grape seed extract (Vitis L. sp.) that exhibited aromatase inhibition in MCF-7aro cells was further tested using an in vivo MCF-7aro xenograft mouse model and found to reduce tumor weight [85]. This study also ascertained that grape seed extract suppressed exon I.3-, exon PII-, and exon I.6-containing aromatase mRNAs in MCF-7 and SK-BR-3 cells, which is interesting since promoters I.3 and II are important promoters for aromatase expression in breast cancer [87, 102, 117]. Furthermore, it was also found reported in this same study that grape seed extract down-regulated the transcription factors cyclic AMP-responsive element binding protein-1 (CREB-1) and glucocorticoid receptor (GR), which are up-regulators of aromatase gene expression [85]. Researchers at the City of Hope Comprehensive Cancer Center's Beckman Research Institute at Duarte, California, have begun recruiting patients for a Phase I clinical trial of IH636 grape seed proanthocyanidin extract in preventing breast cancer in postmenopausal women at risk of developing breast cancer (http://clinicaltrials.gov/ct/show/NCT00100893?order=59). The study lists aromatase inhibition as one of the possible mechanisms of action of grape seed extract.
Numerous other natural product extracts have been reported as “active” but actually, most of these exhibit only marginal to weak inhibition of aromatase (see Table 1).
Table 1
Previous literature reports of natural product extracts tested for aromatase inhibition
| Species Name | Common Name | Family | Type | Extraction Solvent | Assay Type | Activity | Ref.(s) | ||
|---|---|---|---|---|---|---|---|---|---|
| Aesculus glabra | Ohio buckeye | Hippocastanaceae | plant | methanol (CHCl3 partition) | microsomes | 42.0 | PCA at 20 μg/mL | [143] | |
| Agaricus bisporus | baby button mushroom | Agaricaceae | fungus | water reflux | microsomes | ~58 | PCA at 100 μL | [115] | |
| Agaricus bisporus | crimini mushroom | Agaricaceae | fungus | water reflux | microsomes | ~46 | PCA at 100 μL | [115] | |
| Agaricus bisporus | portobello mushroom | Agaricaceae | fungus | water reflux | microsomes | ~45 | PCA at 100 μL | [115] | |
| Agaricus bisporus | stuffing mushroom | Agaricaceae | fungus | water reflux | microsomes | ~20 | PCA at 100 μL | [115] | |
| Agaricus bisporus | white button mushroom | Agaricaceae | fungus | water reflux | microsomes | ~35 | PCA at 100 μL | [115] | |
| Agaricus bisporus | white button mushroom | Agaricaceae | fungus | water reflux | MCF-7aro cells | 14 | at 10 μL/mL | [115] | |
| Agaricus bisporus | white button mushroom | Agaricaceae | fungus | methanol (air dried) | microsomes | 83.1 | PCA at 20 μg/mL | [143] | |
| Agaricus bisporus | white button mushroom | Agaricaceae | fungus | methanol (air dried, hexane partition) | microsomes | 71.1 | PCA at 20 μg/mL | [143] | |
| Agaricus bisporus | white button mushroom | Agaricaceae | fungus | methanol (air dried, CHCl3 partition) | microsomes | 51.7 | PCA at 20 μg/mL | [143] | |
| Agaricus bisporus | white button mushroom | Agaricaceae | fungus | methanol (air dried, water partition) | microsomes | 63.1 | PCA at 20 μg/mL | [143] | |
| Agaricus bisporus | white button mushroom | Agaricaceae | fungus | methanol (air dried, butanol partition) | microsomes | 82.4 | PCA at 20 μg/mL | [143] | |
| Agaricus bisporus | white button mushroom | Agaricaceae | fungus | methanol (dehydrated) | microsomes | 94.4 | PCA at 20 μg/mL | [143] | |
| Agaricus bisporus | white button mushroom | Agaricaceae | fungus | methanol (dehydrated, hexane partition) | microsomes | 55.3 | PCA at 20 μg/mL | [143] | |
| Agaricus bisporus | white button mushroom | Agaricaceae | fungus | methanol (dehydrated, CHCl3 partition) | microsomes | 54.7 | PCA at 20 μg/mL | [143] | |
| Agaricus bisporus | white button mushroom | Agaricaceae | fungus | methanol (dehydrated, water partition) | microsomes | 73.5 | PCA at 20 μg/mL | [143] | |
| Agaricus bisporus | white button mushroom | Agaricaceae | fungus | methanol (dehydrated, butanol partition) | microsomes | 55.0 | PCA at 20 μg/mL | [143] | |
| Agaricus bisporus | white button mushroom | Agaricaceae | fungus | methanol (fresh) | microsomes | 66.4 | PCA at 20 μg/mL | [143] | |
| Agaricus bisporus | white button mushroom | Agaricaceae | fungus | methanol (fresh, hexane partition) | microsomes | 72.7 | PCA at 20 μg/mL | [143] | |
| Agaricus bisporus | white button mushroom | Agaricaceae | fungus | methanol (fresh, CHCl3 partition) | microsomes | 78.8 | PCA at 20 μg/mL | [143] | |
| Agaricus bisporus | white button mushroom | Agaricaceae | fungus | methanol (fresh, water partition) | microsomes | 89.6 | PCA at 20 μg/mL | [143] | |
| Agaricus bisporus | white button mushroom | Agaricaceae | fungus | methanol (fresh, butanol partition) | microsomes | 79.4 | PCA at 20 μg/mL | [143] | |
| Agaricus bisporus | white button mushroom | Agaricaceae | fungus | acetone (fresh) | microsomes | 59.1 | PCA at 20 μg/mL | [143] | |
| Agaricus bisporus | white button mushroom | Agaricaceae | fungus | acetone (fresh, hexane partition) | microsomes | 38.3 | PCA at 20 μg/mL | [143] | |
| Agaricus bisporus | white button mushroom | Agaricaceae | fungus | acetone (fresh, CHCl3 partition) | microsomes | 39.2 | PCA at 20 μg/mL | [143] | |
| Agaricus bisporus | white button mushroom | Agaricaceae | fungus | acetone (fresh, water partition) | microsomes | 81.5 | PCA at 20 μg/mL | [143] | |
| Agaricus bisporus | white button mushroom | Agaricaceae | fungus | acetone (fresh, butanol partition) | microsomes | 85.3 | PCA at 20 μg/mL | [143] | |
| Agaricus bisporus | white button mushroom | Agaricaceae | fungus | water (reflux) | microsomes | 96.2 | PCA at 20 μg/mL | [143] | |
| Agaricus bisporus | white button mushroom | Agaricaceae | fungus | water (reflux, hexane partition) | microsomes | 80.4 | PCA at 20 μg/mL | [143] | |
| Agaricus bisporus | white button mushroom | Agaricaceae | fungus | water (reflux, CHCl3 partition) | microsomes | 56.1 | PCA at 20 μg/mL | [143] | |
| Agaricus bisporus | white button mushroom | Agaricaceae | fungus | water (reflux, water partition) | microsomes | 79.4 | PCA at 20 μg/mL | [143] | |
| Agaricus bisporus | white button mushroom | Agaricaceae | fungus | water (reflux, butanol partition) | microsomes | 65.3 | PCA at 20 μg/mL | [143] | |
| Agaricus bisporus | white button mushroom | Agaricaceae | fungus | methanol (sautéed) | microsomes | 85.8 | PCA at 20 μg/mL | [143] | |
| Agaricus bisporus | white button mushroom | Agaricaceae | fungus | methanol (sautéed, hexane partition) | microsomes | 53.5 | PCA at 20 μg/mL | [143] | |
| Agaricus bisporus | white button mushroom | Agaricaceae | fungus | methanol (sautéed, CHCl3 partition) | microsomes | 68.2 | PCA at 20 μg/mL | [143] | |
| Agaricus bisporus | white button mushroom | Agaricaceae | fungus | methanol (sautéed, water partition) | microsomes | 83.8 | PCA at 20 μg/mL | [143] | |
| Agaricus bisporus | white button mushroom | Agaricaceae | fungus | methanol (sautéed, butanol partition) | microsomes | 57.1 | PCA at 20 μg/mL | [143] | |
| Agaricus bisporus | white button mushroom | Agaricaceae | fungus | Dichloromethane | microsomes | 54.4 | PCA at 20 μg/mL | [143] | |
| Agaricus bisporus | cremini mushroom | Agaricaceae | fungus | Dichloromethane | microsomes | 65.7 | PCA at 20 μg/mL | [143] | |
| Agaricus bisporus | portobella mushroom | Agaricaceae | fungus | Dichloromethane | microsomes | 59.1 | PCA at 20 μg/mL | [143] | |
| Agaricus blazei (1SY16) | almond mushroom | Agaricaceae | fungus | Unknown | microsomes | 87.7 | PCA at 20 μg/mL | [143] | |
| Agaricus blazei | almond mushroom | Agaricaceae | fungus | Methanol | microsomes | 75.2 | PCA at 20 μg/mL | [143] | |
| Agaricus blazei | almond mushroom | Agaricaceae | fungus | methanol (hexane partition) | microsomes | 72.5 | PCA at 20 μg/mL | [143] | |
| Agaricus blazei | almond mushroom | Agaricaceae | fungus | methanol (dichloromethane partition) | microsomes | 82.1 | PCA at 20 μg/mL | [143] | |
| Agaricus blazei | almond mushroom | Agaricaceae | fungus | methanol (water partition) | microsomes | 88.4 | PCA at 20 μg/mL | [143] | |
| Agaricus blazei | almond mushroom | Agaricaceae | fungus | Dichloromethane | microsomes | 74.5 | PCA at 20 μg/mL | [143] | |
| Allium sp.a | green onion | Liliaceae | plant | water reflux | microsomes | ~75 | PCA at 100 μL | [115] | |
| Allium sp.a | green onions | Liliaceae | plant | 70% ethanol | microsomes | 0 | units/100 g | [113] | |
| Allium sp.a | spanish onions | Liliaceae | plant | 70% ethanol | microsomes | 310 | units/100 g | [113] | |
| Allium sp.a | white onions | Liliaceae | plant | 70% ethanol | microsomes | 0 | units/100 g | [113] | |
| Alpinia purpurata | red ginger | Zingerberaceae | plant | 75% MeOH reflux | microsomes | ~78 | % inhib. | [105] | |
| Althaea rosea var. nigra | hollyhock | Malvaceae | plant | Nd | immunocytochemistry in Leydig cells | weak | [181] | ||
| Apium graveolens a | celery | Apiaceae | plant | water reflux | microsomes | ~80 | PCA at 100 μL | [115] | |
| Apium graveolens a | celery | Apiaceae | plant | 70% ethanol | microsomes | 0 | units/100 g | [113] | |
| Asparagus officinalis a | asparagus | Liliaceae | plant | 70% ethanol | microsomes | 1300 | units/100 g | [113] | |
| Auricularia sp. | woodear mushroom | Auriculariaceae | fungus | water reflux | microsomes | ~86 | PCA at 100 μL | [115] | |
| Brassaiopsis glomerulata (leaves) | none | Araliaceae | plant | methanol (hexane partition) | microsomes | 6.9 | PCA at 20 μg/mL | [143] | |
| Brassaiopsis glomerulata (leaves) | none | Araliaceae | plant | methanol (ethyl acetate partition) | microsomes | 59.3 | PCA at 20 μg/mL | [143] | |
| Brassaiopsis glomerulata (leaves) | none | Araliaceae | plant | methanol (water partition) | microsomes | 98.2 | PCA at 20 μg/mL | [143] | |
| Brassaiopsis glomerulata (leaves) | none | Araliaceae | plant | methanol (hexane partition) | SK-BR-3 cells | 7.2 | PCA at 20 μg/mL | [143] | |
| Brassaiopsis glomerulata (leaves) | none | Araliaceae | plant | methanol (ethyl acetate partition) | SK-BR-3 cells | 37.0 | PCA at 20 μg/mL | [143] | |
| Brassaiopsis glomerulata (twigs) | none | Araliaceae | plant | methanol (hexane partition) | microsomes | 35.6 | PCA at 20 μg/mL | [143] | |
| Brassaiopsis glomerulata (twigs) | none | Araliaceae | plant | methanol (ethyl acetate partition) | microsomes | 46.6 | PCA at 20 μg/mL | [143] | |
| Brassaiopsis glomerulata (twigs) | none | Araliaceae | plant | methanol (water partition) | microsomes | 95.8 | PCA at 20 μg/mL | [143] | |
| Brassica juncea a | mustard (greens) | Brassicaceae | plant | 70% ethanol | microsomes | 2700 | units/100 g | [113] | |
| Brassica oleracea a | broccoli | Brassicaceae | plant | water reflux | microsomes | ~85 | [115] | ||
| Brassica oleracea a | broccoli | Brassicaceae | plant | 70% ethanol | microsomes | 0 | units/100 g | [113] | |
| Brassica oleracea a | broccoli (leaves) | Brassicaceae | plant | 70% ethanol | microsomes | 3600 | units/100 g | [113] | |
| Brassica oleracea a | cabbage | Brassicaceae | plant | 70% ethanol | microsomes | 0 | units/100 g | [113] | |
| Brassica oleracea a | cauliflower | Brassicaceae | plant | 70% ethanol | microsomes | 0 | units/100 g | [113] | |
| Brassica oleracea a | collards | Brassicaceae | plant | 70% ethanol | microsomes | 8500 | units/100 g | [113] | |
| Brassica oleracea a | kale | Brassicaceae | plant | 70% ethanol | microsomes | 4700 | units/100 g | [113] | |
| Brassica rapa var. rapaa | turnips | Brassicaceae | plant | 70% ethanol | microsomes | 0 | units/100 g | [113] | |
| Camellia sinensis a | black tea | Theaceae | plant | Nd | nd | >50 | % inhib. | [182] | |
| Camellia sinensis a | green tea | Theaceae | plant | Nd | nd | >50 | % inhib. | [182] | |
| Camellia sinensis a | green tea (polyphenone-60) | Theaceae | plant | Nd | microsomes | 28 | μg/mL IC50 | [112] | |
| Camellia sinensis a | tea | Theaceae | plant | 70% ethanol | microsomes | 27000 | units/100 g | [113] | |
| Cantharellus sp. | chanterelle mushroom | Cantharellaceae | fungus | water reflux | microsomes | ~80 | PCA at 100 μL | [115] | |
| Capsicum annuuma a | bell pepper | Solanaceae | plant | water reflux | microsomes | ~89 | PCA at 100 μL | [115] | |
| Capsicum sp.a | pepper (leaves) | Solanaceae | plant | 70% ethanol | microsomes | 2800 | units/100 g | [113] | |
| Capsicum sp.a | peppers | Solanaceae | plant | 70% ethanol | microsomes | 330 | units/100 g | [113] | |
| Cestrum sp. | none | Solanaceae | plant | 75% MeOH reflux | microsomes | ~40 | % inhib. | [105] | |
| Chrysanthemum partheniuma a | feverfew | Asteraceae | plant | Nd | >50 | % inhib. | [182] | ||
| Cichorium endivia a | endive | Asteraceae | plant | 70% ethanol | microsomes | 850 | units/100 g | [113] | |
| Cichorium endivia a | escarole | Asteraceae | plant | 70% ethanol | microsomes | 830 | units/100 g | [113] | |
| Citrus × limona a | lemons | Rutaceae | plant | 70% ethanol | microsomes | 660 | units/100 g | [113] | |
| Citrus paradisi a | grapefruit (juice) | Rutaceae | plant | Nd | microsomes | ~68 | PCA at 25 μL | [183] | |
| Citrus sinensis a | orange | Rutaceae | plant | 70% ethanol | microsomes | 0 | units/100 g | [113] | |
| Citrus sinensis a | orange (juice) | Rutaceae | plant | Nd | microsomes | ~90 | PCA at 25 μL | [183] | |
| Coccothrinax sp. | none | Arecaceae | plant | 75% MeOH reflux | microsomes | ~70 | % inhib. | [105] | |
| Coffea sp.a | coffee | Rubiaceae | plant | 70% ethanol | microsomes | 13000 | units/100 g | [113] | |
| Coix lachrymal-jobi var. ma-yuen | adlay or Job's tears | Poaceae | plant | Methanol | rat granulose cells | inhibits | activity at 100 μg/mL | [184] | |
| Cucumis melo a | cantaloupe | Cucurbitaceae | plant | 70% ethanol | microsomes | 0 | units/100 g | [113] | |
| Cucumis sativus a | cucumber | Loasaceae | plant | 70% ethanol | microsomes | 0 | units/100 g | [113] | |
| Curcuma longa a | turmeric | Zingiberaceae | plant | Nd | nd | >50 | % inhib. | [182] | |
| Cycas cairnsiana | none | Cycadaceae | plant | 75% MeOH reflux (ethyl acetate partition) | microsomes | 69 | % inhib. | [104] | |
| Cycas revoluta | sago palm | Cycadaceae | plant | 75% MeOH reflux (methanol partition) | microsomes | 79 | % inhib. | [104] | |
| Cycas revoluta | sago palm | Cycadaceae | plant | 75% MeOH reflux (ethyl acetate partition) | microsomes | 86 | % inhib. | [104] | |
| Cycas rumphii | none | Cycadaceae | plant | 75% MeOH reflux (methanol partition) | microsomes | 90 | % inhib. | [104] | |
| Cycas rumphii | none | Cycadaceae | plant | 75% MeOH reflux (ethyl acetate partition) | microsomes | 15 | % inhib. | [104] | |
| Daucus carota a | carrot | Apiaceae | plant | water reflux | microsomes | ~74 | PCA at 100 μL | [115] | |
| Daucus carota a | carrot | Apiaceae | plant | 70% ethanol | microsomes | 0 | units/100 g | [113] | |
| Dioon spinulosum | none | Zamiaceae | plant | 75% MeOH reflux (methanol partition) | microsomes | 40 | % inhib. | [104] | |
| Dioon spinulosum | none | Zamiaceae | plant | 75% MeOH reflux (ethyl acetate partition) | microsomes | 97 | % inhib. | [104] | |
| Encephalartos ferox | bread palm | Zamiaceae | plant | 75% MeOH reflux (methanol partition) | microsomes | 45 | % inhib. | [104] | |
| Encephalartos ferox | bread palm | Zamiaceae | plant | 75% MeOH reflux (ethyl acetate partition) | microsomes | 97 | % inhib. | [104] | |
| Epilobium capense | willowherb | Onagraceae | plant | aqueous methanol | microsomes | 60 | % inhib. at 200 μg | [130] | |
| Epilobium capense | willowherb | Onagraceae | plant | Methanol | microsomes | 54 | % inhib. at 200 μg | [130] | |
| Euonymus alatus | “gui-jun woo” | Celastraceae | plant | water reflux | microsomes | 11 | μg/mL IC50 | [111] | |
| Euonymus alatus | “gui-jun woo” | Celastraceae | plant | water reflux | myometrial cells | 0.80 | μg/mL IC50 | [111] | |
| Euonymus alatus | “gui-jun woo” | Celastraceae | plant | water reflux | leiomyonal cells | 0.07 | μg/mL IC50 | [111] | |
| Flammulina velutipes | enoki mushroom | fungus | water reflux | microsomes | ~78 | PCA at 100 μL | [115] | ||
| Fragaria sp.a | strawberry (juice) | Rosaceae | plant | Nd | microsomes | ~52 | PCA at 25 μL | [183] | |
| Fragaria sp. | strawberry | Rosaceae | plant | Methanol | microsomes | 84.8 | PCA at 20 μg/mL | [143] | |
| Fragaria sp. | strawberry | Rosaceae | plant | Acetone | microsomes | 65.8 | PCA at 20 μg/mL | [143] | |
| Fragaria sp. | strawberry | Rosaceae | plant | methanol/acetone | microsomes | 84.3 | PCA at 20 μg/mL | [143] | |
| Garcinia mangostana | mangosteen | Clusiaceae | plant | Methanol | microsomes | 18.9 | PCA at 20 μg/mL | [109] | |
| Garcinia mangostana | mangosteen | Clusiaceae | plant | methanol (CHCl3 partition) | microsomes | 29.8 | PCA at 20 μg/mL | [109] | |
| Garcinia mangostana | mangosteen | Clusiaceae | plant | Methanol | SK-BR-3 cells | 24.1 | PCA at 20 μg/mL | [109] | |
| Garcinia mangostana | mangosteen | Clusiaceae | plant | methanol (CHCl3 partition) | SK-BR-3 cells | 16.5 | PCA at 20 μg/mL | [109] | |
| Glycyrrhiza glabra a | licorice | Fabaceae | plant | Nd | nd | >50 | % inhib. | [182] | |
| Glyxine max a | soy (infant formulas) | Fabaceae | plant | Nd | in vivo brain aromatase | none | [185] | ||
| Hericium erinaceus | lion's mane mushroom | Hericiaceae | fungus | Dichloromethane | microsomes | 57.9 | PCA at 20 μg/mL | [143] | |
|
Hordeum vulgare
Humulus lupulus | alcohol free beer | Poaceae Cannabaceae | plant | Nd | choriocarcinoma-derived JAR cells | 65.27 | PCA | [114] | |
|
Hordeum vulgare
a
Humulus lupulus a | lager beer | Poaceae Cannabaceae | plant | Nd | choriocarcinoma-derived JAR cells | 75.8 | PCA | [114] | |
|
Hordeum vulgare
a
Humulus lupulus a | stout | Poaceae Cannabaceae | none | Nd | choriocarcinoma-derived JAR cells | 33.9 | PCA | [114] | |
|
Hordeum vulgare
a
Humulus lupulus a | xanthohumol-rich stout | Poaceae Cannabaceae | nd | Nd | choriocarcinoma-derived JAR cells | 26.4 | PCA | [114] | |
| Isodon excisus var. coreanus | none | Lamiaceae | plant | methanol (diethyl ether partition) | microsomes | 13.7 | μg/mL IC50 | [110] | |
| Lactuca sp.a | iceberg lettuce | Asteraceae | plant | 70% ethanol | microsomes | 0 | units/100 g | [113] | |
| Lactuca sp.a | romaine lettuce | Asteraceae | plant | 70% ethanol | microsomes | 560 | units/100 g | [113] | |
| Larrea tridentata a | chaparral | Zygophyllaceae | plant | Nd | nd | >50 | % inhib. | [182] | |
| Lentinula edodes | shiitake mushroom | Marasmiaceae | fungus | water reflux | microsomes | ~62 | PCA at 100 μL | [115] | |
| Lentinus edodes | shiitake mushroom | Marasmiaceae | fungus | Dichloromethane | microsomes | 76.5 | PCA at 20 μg/mL | [143] | |
| Lycopersicon esculentum a | tomato | Solanaceae | plant | 70% ethanol | microsomes | 0 | units/100 g | [113] | |
| Lycopersicon esculentum a | tomato (leaves) | Solanaceae | plant | 70% ethanol | microsomes | 6000 | units/100 g | [113] | |
| Morinda citrifolia | noni | Rubiaceae | plant | Nd | nd | inhibits | [131] | ||
| Murraya paniculata | mock orange | Rutaceae | plant | 75% MeOH reflux | microsomes | ~68 | % inhib. | [105] | |
| Musa sp.a | banana | Musaceae | plant | 70% ethanol | microsomes | 0 | units/100 g | [113] | |
| Nicotiana tabacum a | cigarette smoke | Solanaceae | plant | aqueous trap | microsomes | 0.25 | cigarette equivalents | [113] | |
| Nicotiana tabacum a | cigarette smokea | Solanaceae | plant | methylene chloride trap | microsomes | 0.07 | cigarette equivalents | [113] | |
| Nicotiana tabacum a | tobacco (leaves) | Solanaceae | plant | 70% ethanol | microsomes | 0.025 | cigarette equivalents | [113] | |
| Nicotiana tabacum a | tobacco (leaves) | Solanaceae | plant | 70% ethanol | microsomes | 590 | units/100 g | [113] | |
| Opuntia sp.a | cactus flower | Cactaceae | plant | water (autoclaved) (dichloromethane-methanol partition) | microsomes | ~20 | PCA at 100 μL | [186] | |
| Opuntia sp.a | cactus flower | Cactaceae | plant | water (autoclaved) (diethyl ether subfraction) | microsomes | ~17 | PCA at 100 μL | [186] | |
| Opuntia sp.a | cactus flower | Cactaceae | plant | water (autoclaved) (petroleum ether-diethyl ether subfraction) | microsomes | ~10 | PCA at 100 μL | [186] | |
| Persea americana a | avocado (meat) | Lauraceae | plant | 70% ethanol | microsomes | 0 | units/100 g | [113] | |
| Persea americana a | beet (greens) | Amaranthaceae | plant | 70% ethanol | microsomes | 0 | units/100 g | [113] | |
| Petroselinum crispum a | parsley | Apiaceae | plant | 70% ethanol | microsomes | 1200 | units/100 g | [113] | |
| Piper cubeba | none | Piperaceae | plant | 96% ethanol | enzyme | <10 | μg/mL IC50 | [187] | |
| Pleurotus ostreatus | oyster mushroom | Tricholomataceae | fungus | water reflux | microsomes | ~94 | PCA at 100 μL | [115] | |
| Pleurotus sp. | Italian brown mushroom | Tricholomataceae | fungus | water reflux | microsomes | ~36 | PCA at 100 μL | [115] | |
| Plumbago capensis | leadwort | Plumbaginaceae | plant | 75% MeOH reflux | microsomes | ~8 | % inhib. | [105] | |
| Prunus persica a | peach (juice) | Rosaceae | plant | Nd | microsomes | ~89 | PCA at 25 μL | [183] | |
| Prunus persica a | peach (juice) | Rosaceae | plant | 70% ethanol | microsomes | 0 | units/100 g | [113] | |
| Prunus sp.a | plum (juice) | Rosaceae | plant | Nd | microsomes | ~70 | PCA at 25 μL | [183] | |
| Prunus sp.a | plum | Rosaceae | plant | 70% ethanol | microsomes | 0 | units/100 g | [113] | |
| Pternandra azurea | none | Melastomataceae | plant | methanol (CHCl3 partition) | microsomes | 70.1 | PCA at 20 μg/mL | [143] | |
| Punica granatum | pomegranate | Punicaceae | plant | fermented juice | microsomes | 51 | % inhib. | [188] | |
| Punica granatum | pomegranate | Punicaceae | plant | pericarp polyphenols | microsomes | 24 | % inhib. | [188] | |
| Pyrus malus a | apple (juice) | Rosaceae | plant | Nd | microsomes | ~79 | PCA at 25 μL | [183] | |
| Pyrus malus a | apple | Rosaceae | plant | 70% ethanol | microsomes | <80 | units/100 g | [113] | |
| Renealmia sp. | none | Bromeliaceae | plant | 75% MeOH reflux | microsomes | ~18 | % inhib. | [105] | |
| Riedelia sp. | none | Ericaceae | plant | 75% MeOH reflux | microsomes | ~97 | % inhib. | [105] | |
| Rubus occidentalis | black raspberry | Rosaceae | plant | none (dried fruit) | microsomes | 80.8 | PCA at 20 μg/mL | [143] | |
| Salix sp.a | willow bark | Salicaceae | plant | nd | nd | >50 | % inhib. | [182] | |
| Scutellaria barbata | skullcap | Lamiaceae | plant | water reflux | microsomes | 23 | μg/mL IC50 | [111] | |
| Scutellaria barbata | skullcap | Lamiaceae | plant | water reflux | myometrial cells | 15.00 | μg/mL IC50 | [111] | |
| Scutellaria barbata | skullcap | Lamiaceae | plant | water reflux | leiomyonal cells | 1.01 | μg/mL IC50 | [111] | |
| Solanum melongena a | eggplant | Solanaceae | plant | 70% ethanol | microsomes | 190 | units/100 g | [113] | |
| Solanum melongena a | eggplant (leaves) | Solanaceae | plant | 70% ethanol | microsomes | 800 | units/100 g | [113] | |
| Solanum tuberosum a | potato | Solanaceae | plant | 70% ethanol | microsomes | 0 | units/100 g | [113] | |
| Solanum tuberosum a | potato (leaves) | Solanaceae | plant | 70% ethanol | microsomes | 4500 | units/100 g | [113] | |
| Spinacia oleracea a | spinach | Amaranthaceae | plant | water reflux | microsomes | ~83 | PCA at 100 μL | [115] | |
| Spinacia oleracea a | spinach | Amaranthaceae | plant | 70% ethanol | microsomes | 2400 | units/100 g | [113] | |
| Taraxacum officinale a | dandelion (greens) | Asteraceae | plant | 70% ethanol | microsomes | 2900 | units/100 g | [113] | |
| Theobroma cacao a | chocolate | Sterculiaceae | plant | 70% ethanol | microsomes | 0 | units/100 g | [113] | |
| Theobroma cacao a | cocoa | Sterculiaceae | plant | 70% ethanol | microsomes | 9000 | units/100 g | [113] | |
| Trifolium pratense | red clover (flowers) | Fabaceae | plant | Nd | MCF-7 dual assay for AI and estrogenicity | inhibits | aromatase | [116] | |
| Uncaria tomentosa a | cat's claw | Rubiaceae | plant | Nd | nd | >50 | % inhib. | [182] | |
| Vallaris sp. | none | Apocynaceae | plant | 75% MeOH reflux | microsomes | ~20 | % inhib. | [105] | |
| Viscum album | mistletoe | Viscaceae | plant | 75% MeOH reflux | microsomes | ~94 | % inhib. | [105] | |
| Vitis sp.a | black grape (juice) | Vitaceae | plant | Nd | microsomes | ~23 | PCA at 25 μL | [189] | |
| Vitis sp.a | Cabernet Sauvignon, Glen Ellen Proprietor's Reserve (Sonoma, CA) | Vitaceae | plant | Nd | microsomes | 7.7 | PCA at 50 μL | [86, 106, 107] | |
| Vitis sp.a | Cabernet Sauvignon, San Andrés (Lontué Valley, Chile) | Vitaceae | plant | Nd | microsomes | 0.36 | PCA at 50 μL | [86, 106, 107] | |
| Vitis sp.a | Cabernet Sauvignon, Tanglewood (France) | Vitaceae | plant | Nd | microsomes | 0.29 | PCA at 50 μL | [86, 106, 107] | |
| Vitis sp.a | Champagne grape (juice) | Vitaceae | plant | Nd | microsomes | ~90 | PCA at 25 μL | [189] | |
| Vitis sp.a | Chardonnay, Santa Rita Reserve (Casablanca Valley, Chile) | Vitaceae | plant | Nd | microsomes | 80 | PCA at 50 μL | [86, 106, 107] | |
| Vitis sp.a | Chardonnay, Woodbridge (Woodbridge, CA) | Vitaceae | plant | Nd | microsomes | 99.1 | PCA at 50 μL | [86, 106, 107] | |
| Vitis sp.a | Christmas rose grape (juice) | Vitaceae | plant | Nd | microsomes | ~40 | PCA at 25 μL | [189] | |
| Vitis sp.a | Christmas rose grape (seed) | Vitaceae | plant | Nd | microsomes | ~10 | PCA at 25 μL | [189] | |
| Vitis sp.a | Fumé Blanc, Domaine Napa (Napa Valley, CA) | Vitaceae | plant | Nd | microsomes | 112.5 | PCA at 50 μL | [86, 106, 107] | |
| Vitis sp.a | grape (seed) | Vitaceae | plant | Water | MCF-7aro cells | 70.4 | % inhib. at 40 μg/mL | [85] | |
| Vitis sp.a | grape (seed) | Vitaceae | plant | Water | in vivo MCF-7aro xenograft | reduced | tumor weight | [85] | |
| Vitis sp.a | grape (seed) | Vitaceae | plant | Water | MCF-7aro cells | 80.5 | % inhib. at 60 μg/mL | [85] | |
| Vitis sp.a | grape (seed) | Vitaceae | plant | Water | in vivo MCF-7aro xenograft | reduced | tumor weight | [85] | |
| Vitis sp.a | green seedless grape (juice) | Vitaceae | plant | Nd | microsomes | ~38 | PCA at 25 μL | [189] | |
| Vitis sp.a | Merlot, Forest Ville (Sonoma, CA) | Vitaceae | plant | Nd | microsomes | 0.46 | PCA at 50 μL | [86, 106, 107] | |
| Vitis sp.a | Merlot, Hacienda, 1997 (Sonoma, CA) | Vitaceae | plant | Nd | microsomes | 3.29 | PCA at 50 μL | [86, 106, 107] | |
| Vitis sp.a | Merlot, Hacienda, 1998 (Sonoma, CA) | Vitaceae | plant | Nd | microsomes | 0.9 | PCA at 50 μL | [86, 106, 107] | |
| Vitis sp.a | Merlot, JW Morris Winery (Sonoma, CA) | Vitaceae | plant | Nd | microsomes | 0.42 | PCA at 50 μL | [86, 106, 107] | |
| Vitis sp.a | Pinot Noir, Cambiaso (Healdburg, CA) | Vitaceae | plant | Nd | microsomes | 0.34 | PCA at 50 μL | [86, 106, 107] | |
| Vitis sp.a | Pinot Noir, Hacienda (Sonoma, CA) | Vitaceae | plant | Nd | microsomes | 2.16 | PCA at 50 μL | [86, 106, 107] | |
| Vitis sp.a | Pinot Noir, Hacienda (Sonoma, CA) | Vitaceae | plant | Nd | microsomes | ~8 | PCA at 25 μL | [86, 106, 107] | |
| Vitis sp.a | Pinot Noir, Hacienda (Sonoma, CA) | Vitaceae | plant | Nd | in vivo mouse | inhibits | [86, 106, 107] | ||
| Vitis sp.a | red globe grape (juice) | Vitaceae | plant | Nd | microsomes | ~78 | PCA at 25 μL | [189] | |
| Vitis sp.a | red seedless grape (juice) | Vitaceae | plant | Nd | microsomes | ~29 | PCA at 25 μL | [183] | |
| Vitis sp.a | red seedless grape (juice) | Vitaceae | plant | Nd | MCF-7aro cells | inhibits | aromatase | [183] | |
| Vitis sp.a | red seedless grape (juice) | Vitaceae | plant | Nd | in vivo MCF-7aro xenograft | 70 | % reduced tumor size | [183] | |
| Vitis sp.a | red seedless grape (juice) | Vitaceae | plant | Nd | microsomes | ~30 | PCA at 25 μL | [189] | |
| Vitis sp.a | Sauvignon Blanc, Turning Leaf (Modesto, CA) | Vitaceae | plant | Nd | microsomes | 106.5 | PCA at 50 μL | [86, 106, 107] | |
| Vitis sp.a | seedless grape | Vitaceae | plant | 70% ethanol | microsomes | 0 | units/100 g | [113] | |
| Vitis sp.a | Zinfandel, Black Mountain (San Diego, CA) | Vitaceae | plant | Nd | microsomes | 0.39 | PCA at 50 μL | [86, 106, 107] | |
| Vitis sp.a | Zinfandel, Sequoia Ridge (Graton, CA) | Vitaceae | plant | Nd | microsomes | 0.39 | PCA at 50 μL | [86, 106, 107] | |
| Vitis sp. | grape | Vitaceae | plant | none (dried fruit) | microsomes | 75.7 | PCA at 20 μg/mL | [143] | |
| Zingiber officinale a | ginger (root) | Zingerberaceae | plant | 70% ethanol | microsomes | 0 | units/100 g | [113] | |
| none | propolis | none | misc. | Nd | nd | >50 | %inhib. | [182] | |
nd = no data
NATURAL PRODUCT COMPOUNDS TESTED FOR AROMATASE INHIBITION
Quite a large number of small-molecule natural product secondary metabolites, of various compound classes, have been evaluated for their ability to inhibit the aromatase enzyme. As with the natural product extracts reported in the literature, purified natural products have been tested in a variety of aromatase inhibition assays, with the most common being a noncellular tritiated water release assay using microsomes from different sources, typically from human placentas. Cellular and in vivo aromatase inhibition assays have been utilized to biologically evaluate some of the natural product compounds reported in the literature. Again, assay results have been presented in the literature in numerous forms, complicating the direct comparison of aromatase inhibition potency from compound to compound. For the purposes of this review, compounds are considered strongly active if their IC50 in microsomes was less than 5 μM and/or if their IC50 in cells was less than 10 μM, moderately active if their IC50 in microsomes was less than 10 μM and/or if their IC50 in cells was less than 20 μM, weakly active if their IC50 in microsomes was less than 25 μM and/or if their IC50 in cells was less than 50 μM, and inactive if their IC50 in microsomes was greater than 25 μM and/or if their IC50 in cells was greater than 50 μM. Natural product compounds are discussed according to compound class organized by the group most frequently tested for aromatase inhibition, beginning with flavonoids, followed by other classes listed alphabetically. Up to January 2008, 282 natural product compounds had been reported to be tested for aromatase inhibition in the literature, with 125 flavonoids, 36 terpenoids, 19 peptides, 18 lignans, 16 xanthones, 15 fatty acids, 10 alkaloids, and 43 miscellaneous compounds having been evaluated.
The various types of flavonoids previously tested for aromatase inhibition have comprised 37 flavones, 20 flavanones, 19 chalcones, 10 isoflavans, nine catechins, eight isoflavanones, six isoflavones, five pterocarpans, four rotenoids, two anthocyanins, two flavanols, two homoisoflavonoids, and one coumestan. Of the flavonoids tested, flavones have been tested most often and have been the most active (Table 2, Fig. 3). Chrysin (5,7,4'-trihydroxy-3',5'-dimethoxyflavone, 11) has shown strong aromatase inhibition in microsomes [118–124], JEG-3 cells [125], Arom+HEK 293 cells [125], human preadipocyte cells [126], H295R adrenocortical carcinoma cells [127], and in a MCF-7 dual assay for aromatase inhibition and estrogenicity (chrysin was also estrogenic at high concentrations) [116]. Chrysin (11) did not show activity using trout ovarian aromatase [128] or in endometrial cells [118].
Table 2
Previous literature reports of natural product flavones tested for aromatase inhibition
| Compound Name | Assay Type | Activity | Ref.(s) | |
|---|---|---|---|---|
| apigenin (8) | microsomes | 1.2 | μM IC50 | [122] |
| apigenin (8) | microsomes | 2.9 | μM IC50 | [123] |
| apigenin (8) | microsomes | 4.2 | μM IC50 | [190] |
| apigenin (8) | microsomes | 10 | μM IC50 | [177] |
| apigenin (8) | microsomes | 15 | μM IC50 | [136] |
| apigenin (8) | microsomes | 0.9 | μg/mL IC50 | [121] |
| apigenin (8) | microsomes (modified) | 2.9 | μM IC50 | [124] |
| apigenin (8) | spectrophotometric w/microsomes | 0.9 | Ks | [120] |
| apigenin (8) | trout ovarian aromatase | 84.0 | μM IC50 | [128] |
| apigenin (8) | JEG-3 cells | 0.18 | μM IC50 | [125] |
| apigenin (8) | Arom+HEK 293 cells | 1.4 | μM IC50 | [125] |
| apigenin (8) | H295R adrenocortical carcinoma cells | 20 | μM IC50 | [127] |
| apigenin (8) | granulose-luteal cells | inhibited | at 10 μmol/L for 24 h | [129] |
| ayanin (9) | microsomes | 69.6 | PCA at 20 μg/mL | [143] |
| broussoflavonol F (10) | microsomes | 7.3 | PCA at 20 μg/mL | [143] |
| broussoflavonol F (10) | microsomes | 9.7 | μM IC50 | [135] |
| broussoflavonol F (10) | SK-BR-3 cells | 28.4 | PCA at 50 μM | [143] |
| chrysin (11) | microsomes | 0.5 | μM IC50 | [122] |
| chrysin (11) | microsomes | 0.7 | μM IC50 | [123] |
| chrysin (11) | microsomes | 1.1 | μM IC50 | [191] |
| chrysin (11) | microsomes | 8.9 | μM IC50 | [136] |
| chrysin (11) | microsomes | 1.1 | μg/mL IC50 | [121] |
| chrysin (11) | microsomes | 1 | Ki | [118] |
| chrysin (11) | microsomes | 2.6 | Ki | [119] |
| chrysin (11) | microsomes (modified) | 0.7 | μM IC50 | [124] |
| chrysin (11) | spectrophotometric w/microsomes | 0.5 | Ks | [120] |
| chrysin (11) | trout ovarian aromatase | >1004 | μM IC50 | [128] |
| chrysin (11) | JEG-3 cells | 0.5 | μM IC50 | [125] |
| chrysin (11) | Arom+HEK 293 cells | 0.6 | μM IC50 | [125] |
| chrysin (11) | human preadipocyte cells | 4.6 | μM IC50 | [126] |
| chrysin (11) | H295R adrenocortical carcinoma cells | 7 | μM IC50 | [127] |
| chrysin (11) | MCF-7 dual assay for AI and estrogenicity | inhibits | [116] | |
| chrysin (11) | endometrial stromal cells | none | [118] | |
| chrysin (11) | nd | 11 | μM IC50 | [192] |
| 3',4'-dihydroxyflavone (12) | microsomes | 90 | μM IC50 | [132] |
| 3',4'-dihydroxyflavone (12) | microsomes | 100 | μM IC50 | [136] |
| 3',4'-dihydroxyflavone (12) | microsomes | >200 | μM IC50 | [132] |
| 5,4'-dihydroxyflavone (13) | microsomes | 120 | μM IC50 | [132] |
| 6,4'-dihydroxyflavone (14) | microsomes | 90 | μM IC50 | [132] |
| 7,4'-dihydroxyflavone (15) | microsomes | 2 | μM IC50 | [132] |
| 7,4'-dihydroxyflavone (15) | trout ovarian aromatase | 200.0 | μM IC50 | [128] |
| 7,8-dihydroxyflavone (16) | microsomes | 8 | μM IC50 | [123] |
| 7,8-dihydroxyflavone (16) | microsomes | 2.2 | μg/mL IC50 | [121] |
| 7,8-dihydroxyflavone (16) | microsomes | 10 | Ki | [119] |
| 7,8-dihydroxyflavone (16) | nd | 55 | μM IC50 | [192] |
| 3',4'-dimethoxyflavone (17) | microsomes | 42 | μM IC50 | [136] |
| fisetin (18) | microsomes | 8.5 | μg/mL IC50 | [121] |
| fisetin (18) | JEG-3 cells | 55 | μM IC50 | [125] |
| flavone (19) | microsomes | 8 | μM IC50 | [122] |
| flavone (19) | microsomes | 10 | μM IC50 | [132] |
| flavone (19) | microsomes | 48 | μM IC50 | [123] |
| flavone (19) | microsomes | 67 | μM IC50 | [136] |
| flavone (19) | microsomes | 375.0 | μM IC50 | [128] |
| flavone (19) | microsomes (modified) | 48.0 | μM IC50 | [124] |
| flavone (19) | trout ovarian aromatase | 731.0 | μM IC50 | [128] |
| flavone (19) | human preadipocyte cells | 68 | μM IC50 | [126] |
| flavone (19) | JEG-3 cells | >100 | μM IC50 | [125] |
| flavone (19) | H295R adrenocortical carcinoma cells | none | [127] | |
| galangin (20) | microsomes | 95 | Ki | [119] |
| galangin (20) | JEG-3 cells | 12 | μM IC50 | [125] |
| 3-hydroxyflavone (21) | microsomes | 140 | μM IC50 | [132] |
| 3'-hydroxyflavone (22) | microsomes | 73 | μM IC50 | [136] |
| 4'-hydroxyflavone (23) | microsomes | 180 | μM IC50 | [132] |
| 5-hydroxyflavone (24) | microsomes | 100 | μM IC50 | [132] |
| 6-hydroxyflavone (25) | microsomes | 80 | μM IC50 | [132] |
| 6-hydroxyflavone (25) | JEG-3 cells | 5.5 | μM IC50 | [125] |
| 7-hydroxyflavone (26) | microsomes | 0.2 | μM IC50 | [123] |
| 7-hydroxyflavone (26) | microsomes | 0.5 | μM IC50 | [132] |
| 7-hydroxyflavone (26) | microsomes | 8.2 | μM IC50 | [136] |
| 7-hydroxyflavone (26) | microsomes | 30.5 | μg/mL IC50 | [121] |
| 7-hydroxyflavone (26) | microsomes (modified) | 0.21 | μM IC50 | [124] |
| 7-hydroxyflavone (26) | trout ovarian aromatase | >1001 | μM IC50 | [128] |
| 7-hydroxyflavone (26) | JEG-3 cells | 0.35 | μM IC50 | [125] |
| 7-hydroxyflavone (26) | H295R adrenocortical carcinoma cells | 4 | μM IC50 | [127] |
| isolicoflavonol (27) | microsomes | 0.1 | μM IC50 | [135] |
| kaempferide (28) | JEG-3 cells | 80 | μM IC50 | [125] |
| kaempferol (29) | microsomes | 32 | % inhib. at 50 μM | [130] |
| kaempferol (29) | JEG-3 cells | 11 | μM IC50 | [125] |
| kaempferol (29) | preadipose cells | 61 | μM IC50 | [134] |
| kaempferol 7,4'-dimethyl ether (30) | microsomes | 45.6 | PCA at 20 μg/mL | [143] |
| kaempferol 7,4'-dimethyl ether (30) | SK-BR-3 cells | 99.2 | PCA at 50 μM | [143] |
| luteolin (31) | microsomes | 8.6 | μM IC50 | [136] |
| luteolin (31) | microsomes | 3.3 | μg/mL IC50 | [121] |
| luteolin (31) | microsomes (modified) | 1.2 | μM IC50 | [133] |
| luteolin (31) | spectrophotometric w/microsomes | 1.0 | Ks | [120] |
| luteolin (31) | JEG-3 cells | 2 | μM IC50 | [125] |
| luteolin (31) | preadipose cells | 25 | μM IC50 | [134] |
| 7-methoxyflavone (32) | microsomes | 3.2 | μM IC50 | [123] |
| 7-methoxyflavone (32) | microsomes (modified) | 3.2 | μM IC50 | [124] |
| 7-methoxyflavone (32) | H295R adrenocortical carcinoma cells | none | [127] | |
| morin (33) | spectrophotometric w/microsomes | 5.0 | Ks | [120] |
| myricetin (34) | microsomes | 5.6 | μg/mL IC50 | [121] |
| myricetin (34) | microsomes | 41 | % inhib. at 50 μM | [130] |
| myricetin (34) | spectrophotometric w/microsomes | 5.6 | Ks | [120] |
| oxyayanin B (35) | microsomes | 83.0 | PCA at 20 μg/mL | [143] |
| prunetin (36) | microsomes | none | μM IC50 | [123] |
| prunetin (36) | microsomes | 7.8 | μg/mL IC50 | [121] |
| quercetin (37) | microsomes | 12 | μM IC50 | [122] |
| quercetin (37) | microsomes | 35 | % inhib. at 50 μM | [130] |
| quercetin (37) | spectrophotometric w/microsomes | 4.7 | Ks | [120] |
| quercetin (37) | trout ovarian aromatase | 139.0 | μM IC50 | [128] |
| quercetin (37) | JEG-3 cells | >100 | μM IC50 | [125] |
| quercetin (37) | H295R adrenocortical carcinoma cells | none | [127] | |
| quercetin (37) | human preadipocyte cells | none | [126] | |
| quercetin (37) | granulose-luteal cells | none | at 10 μmol/L for 24h | [129] |
| quercetin (37) | nd | ~85 | % inhib. at 100 μM | [107] |
| quercetin (37) | nd | nd | [131] | |
| robinetin (38) | microsomes | 45.7 | μg/mL IC50 | [121] |
| rutin (39) | human preadipocyte cells | none | [126] | |
| rutin (39) | nd | ~120 | % inhib. at 100 μM | [107] |
| 7,3',4',5'-tetrahydroxyflavone (40) | microsomes | 45 | μM IC50 | [136] |
| 5,7,2',4'-tetrahydroxy- 3-geranylflavone (41) | microsomes | 24.0 | μM IC50 | [135] |
| 7,3',4'-trihydroxyflavone (42) | microsomes | 38 | μM IC50 | [136] |
| 5,7,3'-trihydroxy-4'- methoxyflavone (43) | microsomes | 27 | μM IC50 | [136] |
| 5,7,4'-trihydroxy-3'- methoxyflavone (44) | microsomes | 7.2 | μM IC50 | [136] |
nd = no data
Apigenin (5,7,4'-trihydroxyflavone, 8) and quercetin (3,5,7,3',4'-pentahydroxyflavone, 37) have been tested numerous times for aromatase inhibition. Apigenin (8) was found to be strongly active in microsomes [121–124], JEG-3 cells [125], Arom+HEK 293 cells [125], and granulose-luteal cells [129]. However, this flavone was found to be only moderately active in H295R adrenocortical carcinoma cells [127] and was not active using trout ovarian aromatase [128]. The pentahydroxylated flavone, quercetin (37), present in numerous plant species but reported in the aromatase literature as being isolated from Epilobium capense [130] and Morinda citrifolia L. (noni) [131], was found to be moderately active in two microsomal studies [120, 122] but only weakly active in another microsomal study [130]. Quercetin (37) was not active in granulose-luteal cells [129], JEG-3 cells [125], H295R adrenocortical carcinoma cells [127], human preadipocyte cells [126], or using trout ovarian aromatase [128].
Reports of activity for unsubstituted flavone (19), a natural product derivative, have ranged from moderately active (8 μM IC50) [122] to inactive (375.0 μM IC50) [128] in microsomes. Flavone (19) was found to be weakly active in human preadipocyte cells [126] but inactive in JEG-3 cells [125], H295R adrenocortical carcinoma cells [127], and using trout ovarian aromatase [128].
7-Hydroxyflavone (26) has been tested several times and has shown strong aromatase inhibition in most microsomal assay testing [123, 124, 132]. 7-Hydroxyflavone (26) also exhibited strong activity in JEG-3 cells [125] and H295R adrenocortical carcinoma cells [127] but was not active using trout ovarian aromatase [128]. Luteolin (5,7,3',4'-tetrahydroxyflavone, 31) has shown strong activity in microsomal testing [120, 121, 133] and cellular testing with JEG-3 cells [125]. Luteolin (31) was only moderately active in preadipose cells [134]. 7,8-Dihydroxyflavone (16) was tested four times and has shown strong to moderate activity in microsomal testing [121, 123].
Of the flavones tested three or less times, those with strong activity include 6-hydroxyflavone (25) in JEG-3 cells [125], 7,4'-dihydroxyflavone (15) in microsomes [132], 7-methoxyflavone (32) in microsomes [123, 124] but not in H295R adrenocortical carcinoma cells [127], and isolicoflavonol (3,5,7-trihydroxy-3'-prenylflavone, 27, isolated from Broussonetia papyrifera) in microsomes [135]. Moderately active flavones included broussoflavonol F (3,5,7-trihydroxy-8,3'-diprenylflavone, 10, isolated from B. papyrifera Vent.) in microsomes [135], galangin (3,5,7-trihydroxyflavone, 20) in JEG-3 cells [125], kaempferol (3,5,7,4'-tetrahydroxyflavone, 29) in JEG-3 cells [125], 5,7,4'-trihydroxy-3'-methoxyflavone (44) in microsomes [136], and rutin (5,7,3',4'-tetrahydroxyflavone 3-diglucoside, 39, isolated from Vitis L. sp.) [107].
When comparing aromatase inhibitory activity within the flavone compound class, several trends become apparent. Hydroxyl groups at positions 5, 7, and 4' generally increase aromatase inhibition activity [e.g., as in apigenin (8), luteolin (31), chrysin (11), and isolicoflavonol (27)], although hydroxylation at these positions is not always enough to provide strong aromatase inhibition [e.g., morin (33), quercetin (37)]. Methoxylation generally decreases aromatase inhibition activity [e.g., 7-hydroxyflavone (26) was more active than 7-methoxyflavone (32), apigenin (8) was more active than prunetin (36), and kaempferol (29) was more active than kaempferide (28)] except in the case of chrysin (11), which has two methoxyl groups and is one of the most active flavones tested thus far. Substitution at the C-3 position generally reduces activity [e.g., 3-hydroxyflavone (21), morin (33), quercetin (37), myricetin (34) and robinetin (38), which were all inactive or only weakly active], while prenylation seems to increase activity, as exemplified by isolicoflavonol (27) and broussoflavonol F (10).
Twenty flavanones have been tested for aromatase inhibition in the literature (Table 3, Fig. 4). Of these, naringenin (5,7,4'-flavanone, 59) has been tested most often and has shown strong to moderate aromatase inhibition activity in microsomal testing [118, 119, 123, 124]. This substance was found to be active in JEG-3 cells [125], Arom+HEK 293 cells [125], and inhibited aromatase at low concentrations in a MCF-7 dual assay for aromatase inhibition and estrogenicity [naringenin (59) was also estrogenic at high concentrations] [116]. Naringenin (59) was less active in H295R adenocortical carcinoma cells [127]. The (2S) stereoisomer of naringenin (59, isolated from Broussonetia papyrifera Vent.) [135] was less active than naringenin (59) when no stereochemistry was indicated.
Table 3
Previous literature reports of natural product flavanones tested for aromatase inhibition
| Compound Name | Assay Type | Activity | Ref.(s) | |
|---|---|---|---|---|
| (2S)-abyssinone II (45) | microsomes | 0.4 | μM IC50 | [135] |
| 3',4'-dihydroxyflavanonea (46) | microsomes | 160 | μM IC50 | [132] |
| 5,7-dihydroxyflavanonea (47) | microsomes | 10 | μM IC50 | [136] |
| 7,8-dihydroxyflavanonea (48) | microsomes (modified) | 8.0 | μM IC50 | [124] |
| (2S)-2',4'-dihydroxy-2”-(1-hydroxy-1-methylethyl)dihydrofuro[2,3-h]flavanone (49) | microsomes | 0.1 | μM IC50 | [135] |
| eriodictyola (50) | microsomes | 5.3 | μM IC50 | [136] |
| eriodictyola (50) | microsomes (modified) | 0.6 | μM IC50 | [133] |
| (2S)-euchrenone a7 (51) | microsomes | 3.4 | μM IC50 | [135] |
| flavanonea (52) | microsomes | 8 | μM IC50 | [122] |
| flavanonea (52) | microsomes | 8 | μM IC50 | [132] |
| flavanonea (52) | microsomes | 28.5 | μM IC50 | [137] |
| flavanonea (52) | microsomes | 32 | μM IC50 | [136] |
| flavanonea (52) | microsomes | 250.0 | μM IC50 | [128] |
| flavanonea (52) | microsomes | 8.7 | μg/mL IC50 | [121] |
| flavanonea (52) | microsomes (modified) | 13.8 | μM IC50 | [133] |
| flavanonea (52) | trout ovarian aromatase | >1000 | μM IC50 | [128] |
| hesperetina (53) | microsomes | 1.0 | μg/mL IC50 | [121] |
| hesperetina (53) | microsomes (modified) | 3.3 | μM IC50 | [133] |
| hesperidina (54) | microsomes | 40.9 | μg/mL IC50 | [121] |
| 4'-hydroxyflavanonea (55) | microsomes | 10 | μM IC50 | [132] |
| 7-hydroxyflavanonea (56) | microsomes | 3.8 | μM IC50 | [138] |
| 7-hydroxyflavanonea (56) | microsomes | 10 | μM IC50 | [136] |
| 7-hydroxyflavanonea (56) | microsomes (modified) | 2.4 | μM IC50 | [133] |
| 7-hydroxyflavanonea (56) | H295R adrenocortical carcinoma cells | 65 | μM IC50 | [127] |
| isoxanthohumola (57) | choriocarcinoma-derived JAR cells | 139.7 | μM IC50 | [114] |
| isoxanthohumola (57) | SK-BR-3 cells | 25.4 | μM IC50 | [139] |
| 7-methoxyflavanonea (58) | microsomes | 8.0 | μM IC50 | [137] |
| 7-methoxyflavanonea (58) | microsomes (modified) | 2.6 | μM IC50 | [124] |
| 7-methoxyflavanonea (58) | H295R adrenocortical carcinoma cells | none | [127] | |
| naringenin (59a) | microsomes | 2.9 | μM IC50 | [191] |
| naringenin (59a) | microsomes | 9.2 | μM IC50 | [123] |
| (2S)-naringenin (59) | microsomes | 17.0 | μM IC50 | [135] |
| naringenin (59a) | microsomes | 0.3 | Ki | [118] |
| naringenin (59a) | microsomes | 5.1 | Ki | [119] |
| naringenin (59a) | microsomes (modified) | 9.2 | μM IC50 | [124] |
| naringenin (59a) | JEG-3 cells | 1.4 | μM IC50 | [125] |
| naringenin (59a) | Arom+HEK 293 cells | 3.2 | μM IC50 | [125] |
| naringenin (59a) | H295R adrenocortical carcinoma cells | 85 | μM IC50 | [127] |
| naringenin (59a) | MCF-7 dual assay for AI and estrogenicity | inhibits | [116] | |
| naringenin (59a) | rat granulose cells | inhibits | [184] | |
| naringenin (59a) | endometrial stromal cells | none | [118] | |
| naringin (60) | microsomes | 1.8 | μg/mL IC50 | [121] |
| pinostrobina (61) | JEG-3 cells | 4 | μM IC50 | [125] |
| 8-prenylnaringenina (62) | microsomes | 0.2 | μM IC50 | [191] |
| 8-prenylnaringenina (62) | choriocarcinoma-derived JAR cells | 0.065 | μM IC50 | [114] |
| 8-prenylnaringenina (62) | SK-BR-3 cells | 0.08 | μM IC50 | [139] |
| 8-prenylnaringenina (62) | breast adipose fibroblast cells | 0.3 | μM IC50 | [191] |
| (2S)-5,7,2',4'-tetrahydroxyflavanone (63) | microsomes | 2.2 | μM IC50 | [135] |
| 5,7,4'-trihydroxy-3'-methoxyflavanone (64) | microsomes | 25 | μM IC50 | [136] |
Unsubstituted flavanone (52), a natural product derivative, was found to range from having moderate aromatase inhibition [121, 122, 132, 133, 137] to being inactive [128] in microsomal biological evaluations. Flavanone (52) was inactive using trout ovarian aromatase [128]. 7-Hydroxyflavanone (56) and 7-methoxyflavanone (58) were both found to be aromatase inhibitors in microsomes [133, 137, 138], with 7-hydroxyflavanone (56) exhibiting more potent activity than 7-methoxyflavanone (58). 7-Hydroxyflavanone (56) was also active in H295R cells but 7-methoxyflavanone was inactive [127]. Hesperetin (5,7,3'-trihydroxy-4'-methoxyflavanone, 53) [121, 133] and eriodictyol (5,7,3',4'-tetrahydroxyflavanone, 50) [133] were each tested twice in microsomal aromatase assays and found to be strongly active. 8-Prenylnaringenin (62, isolated from Humulus lupulus L.) was one of the most active natural product compounds tested for aromatase inhibition in both microsomes and cell assays [114, 139].
Of the flavanones tested only once, (2S)-2',4'-dihydroxy-2”-(1-hydroxy-1-methylethyl)dihydrofuro[2,3-h]flavanone (49, isolated from Broussonetia papyrifera Vent.) [135], (2S)-abyssinone II (45, isolated from B. papyrifera), (2S)-5,7,2',4'-tetrahydroxyflavanone (63, isolated from B. papyrifera), (2S)-euchrenone a7 (51, isolated from B. papyrifera), 7,8-dihydroxyflavanone (48) [124], and naringin (60) [121] were found to be potent aromatase inhibitors using microsomal assays. Pinostrobin (5-hydroxy-7-methoxyflavanone, 61) [125] was found to be active in JEG-3 cells [125].
When comparing the activity within the flavanone compound class, several trends are noticeable. Hydroxyl groups at positions 7 and 4' generally increases aromatase inhibition [e.g., eriodictyol (50), (2S)-abyssinone II (45), and (2S)-euchrenone a7 (51)]. Methoxylation, however, decreases activity [e.g., 7-hydroxyflavanone (56) was more active than 7-methoxyflavanone (58)]. Prenylation generally caused substantial increases in aromatase activity [e.g., 8-prenylnaringenin (62), (2S)-abyssinone II (45), and (2S)-euchrenone a7 (51)] except in the case of isoxanthohumol (57).
Nineteen chalcones have been tested for their ability to inhibit aromatase (Table 4, Fig. 5). 3'-[γ-Hydroxymethyl-(E)-γ-methylallyl]-2,4,2',4'-tetrahydroxychalcone 11'-O-coumarate (75, isolated from Broussonetia papyrifera Vent.) [135], naringenin chalcone (4,2',4',6'-tetrahydroxychalcone, 78) [133], eriodictyol chalcone (3,4,2',4',6'-pentahydroxychalcone, 68) [133], and 2,4,2',4'-tetrahydroxy-3'-prenylchalcone (82, isolated from B. papyrifera) were the most active of the chalcones tested in microsomal assays. Butein (3,4,2',4'-tetrahydroxychalcone, 65) was active in MCF-7aro cells [140], while xanthohumol (4,4',6'-trihydroxy-2'-methoxy-5'-prenylchalcone, 83, isolated from Humulus lupulus L.) was active in SK-BR-3 cells [139]. Isoliquiritigenin (4,2',4'- trihydroxychalcone, 77) isolated from licorice (Glycyrrhiza glabra L.) [141] and tonka bean (Dipteryx odorata Willd.) [142], was found to be inactive in microsomes [133, 143] but strongly active in SK-BR-3 cells [143]. Isogemichalcone C (76) was also moderately active in a microsomal assay [135].
Table 4
Previous literature reports of natural product chalcones tested for aromatase inhibition
| Compound Name | Assay Type | Activity | Ref.(s) | |
|---|---|---|---|---|
| butein (65) | MCF-7aro cells | 3.70 | μM IC50 | [140] |
| 4,2'-dihydroxychalcone (66) | microsomes (modified) | >50 | μM IC50 | [133] |
| 2',4'-dihydroxychalcone (67) | microsomes (modified) | >50 | μM IC50 | [133] |
| eriodictyol chalcone (68) | microsomes (modified) | 2.8 | μM IC50 | [133] |
| hesperetin chalcone (69) | microsomes (modified) | 24.2 | μM IC50 | [133] |
| 2-hydroxychalcone (70) | MCF-7aro cells | ~45 | PCA at 20 μM | [140] |
| 2'-hydroxychalcone (71) | microsomes (modified) | >50 | μM IC50 | [133] |
| 2'-hydroxychalcone (71) | MCF-7aro cells | ~30 | PCA at 20 μM | [140] |
| 4-hydroxychalcone (72) | microsomes (modified) | >50 | μM IC50 | [133] |
| 4-hydroxychalcone (72) | MCF-7aro cells | ~60 | PCA at 20 μM | [140] |
| 4'-hydroxychalcone (73) | microsomes (modified) | 30.6 | μM IC50 | [133] |
| 2-hydroxy-4-methoxychalcone (74) | microsomes (modified) | >50 | μM IC50 | [133] |
| 3'-[γ-hydroxymethyl-(E)-γ-methylallyl]-2,4,2',4'-tetrahydroxychalcone 11'-O-coumarate (75) | microsomes | 0.5 | μM IC50 | [135] |
| isogemichalcone C (76) | microsomes | 7.1 | μM IC50 | [135] |
| isoliquiritigenin (77) | microsomes | 30.6 | PCA at 20 μg/mL | [143] |
| isoliquiritigenin (77) | microsomes (modified) | 34.6 | μM IC50 | [133] |
| isoliquiritigenin (77) | SK-BR-3 cells | 9.3 | PCA at 50 μM | [143] |
| isoliquiritigenin (77) | MCF-7aro cells | ~60 | PCA at 20 μM | [140] |
| naringenin chalcone (78) | microsomes (modified) | 2.6 | μM IC50 | [133] |
| paratocarpin B (79) | microsomes | 58.1 | PCA at 20 μg/mL | [143] |
| phloretin (80) | microsomes (modified) | >50 | μM IC50 | [133] |
| pinostrobin chalcone (81) | microsomes (modified) | 14.3 | μM IC50 | [133] |
| 2,4,2',4'-tetrahydroxy-3'-prenylchalcone (82) | microsomes | 3.3 | PCA at 20 μg/mL | [143] |
| 2,4,2',4'-tetrahydroxy-3'-prenylchalcone (82) | microsomes | 4.6 | μM IC50 | [135] |
| 2,4,2',4'-tetrahydroxy-3'-prenylchalcone (82) | SK-BR-3 cells | 10.6 | PCA at 50 μM | [143] |
| xanthohumol (83) | SK-BR-3 cells | 3.2 | μM IC50 | [139] |
| xanthohumol (83) | choriocarcinoma-derived JAR cells | 20.3 | μM IC50 | [114] |
A couple of trends are discernible when comparing the aromatase inhibitory activity of structures within the chalcone compound class. Hydroxyl groups at positions 4, 2', and 4' have generally provided compounds with a greater degree of aromatase inhibition. The 1,2 double bond is necessary for activity [e.g., phloretin (80) was inactive while naringenin chalcone (78) was active]. In addition, methoxylation generally reduces activity [e.g., eriodictyol chalcone (68) was considerably more active than hesperetin chalcone (69); 3'-[γ-hydroxymethyl-(E)-γ-methylallyl]-2,4,2',4'-tetrahydroxychalcone 11'-O-coumarate (75) was more active than isogemichalcone C (76)].
Ten isoflavans were tested with four isoflavans found to be weakly active (Table 5, Fig. 6). 4'-O-Methylglabridin (90), isolated from licorice (Glycyrrhiza glabra L.), leiocin (87), isolated from Berchemia discolor Hemsl. [144], leiocinol (88), isolated from B. discolor, and methylequol (89) [145] were all weakly active in the microsomal assay.
Table 5
Previous literature reports of natural product isoflavans tested for aromatase inhibition
| Compound Name | Assay Type | Activity | Ref.(s) | |
|---|---|---|---|---|
| equol (84) | microsomes | 150 | μM IC50 | [145] |
| equol (84) | microsomes | 850.0 | μM IC50 | [128] |
| equol (84) | trout ovarian aromatase | 793.0 | μM IC50 | [128] |
| equol (84) | human preadipocyte cells | none | [126] | |
| heminitidulan (85) | microsomes | 45.1 | PCA at 20 μg/mL | [143] |
| 3'-hydroxy-4'-O-methylglabridin (86) | microsomes | 70.0 | PCA at 20 μg/mL | [143] |
| leiocin (87) | microsomes | 28.6 | PCA at 20 μg/mL | [143] |
| leiocin (87) | SK-BR-3 cells | 85.5 | PCA at 50 μM | [143] |
| leiocinol (88) | microsomes | 36.9 | PCA at 20 μg/mL | [143] |
| leiocinol (88) | SK-BR-3 cells | 101.8 | PCA at 50 μM | [143] |
| methylequol (89) | microsomes | 20 | μM IC50 | [145] |
| 4'-O-methylglabridin (90) | microsomes | 25.2 | PCA at 20 μg/mL | [143] |
| 4'-O-methylglabridin (90) | SK-BR-3 cells | 71.2 | PCA at 50 μM | [143] |
| nitidulan (91) | microsomes | 47.1 | PCA at 20 μg/mL | [143] |
| nitidulan (91) | SK-BR-3 cells | 59.1 | PCA at 50 μM | [143] |
| nitidulin (92) | microsomes | 71.2 | PCA at 20 μg/mL | [143] |
| sativan (93) | microsomes | >50 | μM IC50 | [123] |
Nine catechins were reported as being tested for their ability to inhibit aromatase (Table 6, Fig. 7). Epigallocatechin gallate [EGCG, 99, isolated from Camellia sinensis Kuntze (green tea)], has been tested four times with results ranging from weakly active [146], when steroechemistry was not reported, to inactive for the (−) stereoisomer [112], in microsomal testing. However, an epidemiological study inferring aromatase inhibition through changes in estradiol levels demonstrated that estradiol levels were lower for people with higher EGCG (99) intake [147]. Furthermore, EGCG (99) has been tested using an in vivo Swiss-Webster mouse model measuring ovarian aromatase activity and was found to inhibit aromatase activity by 56% at 25 and 12.5 mg/kg [148]. Theaflavin (101) and theaflavin-3,3'-gallate (102), both isolated from Camellia sinensis Kuntze (black tea), were found to strongly inhibit aromatase in microsomes [146]. (−)-Gallocatechin gallate (100), isolated from C. sinensis (green tea), was found to weakly inhibit aromatse in microsomes [112]. All other catechins tested were found to be inactive.
Table 6
Previous literature reports of natural product catechins tested for aromatase inhibition
| Compound Name | Assay Type | Activity | Ref.(s) | |
|---|---|---|---|---|
| (+)-catechin (94) | microsomes | 100.0 | PCA at 20 μg/mL | [143] |
| (+)-catechin (94) | microsomes | none | [112] | |
| (+)-catechin (94) | H295R adrenocortical carcinoma cells | none | [127] | |
| catechin (94a) | human preadipocyte cells | none | [126] | |
| (−)-catechin gallate (95) | microsomes | 55 | μM IC50 | [112] |
| (−)-epicatechin (96) | microsomes | 94.9 | PCA at 20 μg/mL | [143] |
| (−)-epicatechin (96) | microsomes | none | [112] | |
| (−)-epicatechin (96) | H295R adrenocortical carcinoma cells | none | [127] | |
| (−)-epicatechin-3-O-gallate (97) | microsomes | 67.1 | PCA at 20 μg/mL | [143] |
| (−)-epicatechin gallate (97) | microsomes | 20 | % inhib. at 100 μM | [112] |
| epicatechin gallate (97a) | in vivo Swiss-Webster mice ovarian aromatase activity | none | [148] | |
| (−)-epigallocatechin (98) | microsomes | 75.3 | PCA at 20 μg/mL | [143] |
| (−)-epigallocatechin (98) | microsomes | 100 | μM IC50 | [112] |
| (−)-epigallocatechin-3-O-gallate (99) | microsomes | 54.9 | PCA at 20 μg/mL | [143] |
| epigallocatechin gallate (99a) | microsomes | 13.79 | μM IC50 | [146] |
| (−)-epigallocatechin gallate (99) | microsomes | 60 | μM IC50 | [112] |
| epigallocatechin gallate (99a) | in vivo Swiss-Webster mice ovarian aromatase activity | 56 | % inhib. at 25 μg/kg | [148] |
| epigallocatechin gallate (99a) | epidemiological E2 levels | lower | E2 levels with higher EGCG intake | [147] |
| (−)-gallocatchin gallate (100) | microsomes | 15 | μM IC50 | [112] |
| theaflavin (101) | microsomes | 4.17 | μM IC50 | [146] |
| theaflavin-3,3'-digallate (102) | microsomes | 3.45 | μM IC50 | [146] |
Aromatase inhibition testing has been reported for eight isoflavanones (103–110, Table 7, Fig. 8), with all isoflavanones found to be inactive in microsome testing [132, 143].
Table 7
Previous literature reports of natural product isoflavanones tested for aromatase inhibition
| Compound Name | Assay Type | Activity | Ref.(s) | |
|---|---|---|---|---|
| 3',4'-dihydroxyisoflavanone (103) | microsomes | >200 | μM IC50 | [132] |
| discoloranone A (104) | microsomes | 85.8 | PCA at 20 μg/mL | [143] |
| discoloranone B (105) | microsomes | 53.5 | PCA at 20 μg/mL | [143] |
| 2-hydroxyisoflavanone (106) | microsomes | 170 | μM IC50 | [132] |
| 4'-hydroxyisoflavanone (107) | microsomes | 160 | μM IC50 | [132] |
| isodiscoloranone A (108) | microsomes | 91.5 | PCA at 20 μg/mL | [143] |
| isodiscoloranone B (109) | microsomes | 57.2 | PCA at 20 μg/mL | [143] |
| isoflavanone (110) | microsomes | 120 | μM IC50 | [132] |
From the literature, six isoflavones were tested for aromatase inhibition (Table 8, Fig. 9). The isoflavone biochanin A (5,7-dihydroxy-4'-methoxyisoflavone, 111) was reported as either moderately active [121] or inactive [119, 123, 149] in microsomal assays but was strongly active in JEG-3 cells [125] and inactive in granulose-luteal cells [129], human preadipocyte cells [126], and against trout ovarian aromatase [128]. However, biochanin A (111) did inhibit aromatase at low concentrations using a MCF-7 dual assay for aromatase inhibition and estrogenicity and was estrogenic at high concentrations [116]. None of the other isoflavones inhibited aromatase.
Table 8
Previous literature reports of natural product isoflavones tested for aromatase inhibition
| Compound Name | Assay Type | Activity | Ref.(s) | |
|---|---|---|---|---|
| biochanin A (111) | microsomes | 18.9 | μg/mL IC50 | [121] |
| biochanin A (111) | microsomes | 49 | μM IC50 | [123] |
| biochanin A (111) | microsomes | 94.50 | μM IC50 | [149] |
| biochanin A (111) | microsomes | 10.2 | μg/mL IC50 | [121] |
| biochanin A (111) | microsomes | 12 | Ki | [119] |
| biochanin A (111) | trout ovarian aromatase | >1000 | μM IC50 | [128] |
| biochanin A (111) | JEG-3 cells | 4 | μM IC50 | [125] |
| biochanin A (111) | human preadipocyte cells | 113 | μM IC50 | [126] |
| biochanin A (111) | granulosa-luteal cells | none | at 10 μmol/L for 24 h | [129] |
| biochanin A (111) | MCF-7 dual assay for AI and estrogenicity | inhibits | [116] | |
| daidzein (112) | microsomes | none | μM IC50 | [123] |
| daidzein (112) | microsomes | >50 | Ki | [118] |
| daidzein (112) | microsomes | none | [145] | |
| daidzein (112) | trout ovarian aromatase | >1002 | μM IC50 | [128] |
| daidzein (112) | endometrial stromal cells | none | [118] | |
| daidzein (112) | human preadipocyte cells | none | [126] | |
| formononetin (113) | microsomes | 75.7 | PCA at 20 μg/mL | [143] |
| formononetin (113) | microsomes | none | μM IC50 | [123] |
| formononetin (113) | MCF-7 dual assay for AI and estrogenicity | inhibits | [116] | |
| genistein (114) | microsomes | none | μM IC50 | [123] |
| genistein (114) | microsomes | >50 | Ki | [118] |
| genistein (114) | microsomes | 123 | Ki | [119] |
| genistein (114) | microsomes | none | [149] | |
| genistein (114) | microsomes (modified) | none | μM IC50 | [124] |
| genistein (114) | trout ovarian aromatase | >1003 | μM IC50 | [128] |
| genistein (114) | endometrial stromal cells | none | [118] | |
| genistein (114) | MCF-7 dual assay for AI and estrogenicity | none | [116] | |
| genistein (114) | H295R adrenocortical carcinoma cells | none | [127] | |
| genistein (114) | human preadipocyte cells | none | [126] | |
| isoflavone (115) | microsomes | >200 | μM IC50 | [132] |
| 7,3',4' -trihydroxyisoflavone (116) | microsomes | none | μM IC50 | [123] |
Sixteen miscellaneous flavonoids were tested for their ability to inhibit aromatase (Table 9, Fig. 10). The coumestan, coumestrol (119), has been tested five times for aromatase activity and results have ranged from weakly active [123] in microsomal testing to moderately active in preadipose cells [134]. The only other miscellaneous flavonoid found to be active was a rotenoid, rotenone (132, a commercially available insecticide and a potent respiratory toxin), which was found to be strongly active in H295R adrenocortical carcinoma cells [127]. None of the flavanols, homoisoflavonoids, or pterocarpans were found to be active.
Structures of natural product flavonoids (not previously mentioned) tested for aromatase inhibition.
Table 9
Previous literature reports of natural product flavonoids (not previously mentioned) tested for aromatase inhibition (listed alphabetically by compound class)
| Compound Name | Compound Class | Assay Type | Activity | Ref.(s) | |
|---|---|---|---|---|---|
| cyanidin (117) | anthocyanin | microsome | 72 | μM IC50 | [136] |
| malvidin-3-O-glucoside (118) | anthocyanin | microsome | 299 | μM IC50 | [136] |
| coumestrol (119) | coumestan | microsomes | 25 | μM IC50 | [123] |
| coumestrol (119) | coumestan | microsomes (modified) | 50.6 | % inhib. at 50 μM | [154] |
| coumestrol (119) | coumestan | microsomes (modified) | 35.0 | μM IC50 | [124] |
| coumestrol (119) | coumestan | trout ovarian aromatase | >1000 | μM IC50 | [128] |
| coumestrol (119) | coumestan | preadipose cells | 17 | μM IC50 | [134] |
| flavan-4-ol (120) | flavanol | microsomes | 120 | μM IC50 | [132] |
| 4'-hydroxyflavan-4-ol (121) | flavanol | microsomes | >200 | μM IC50 | [132] |
| bonducellin (122) | homoisoflavonoid | microsomes | 65.0 | PCA at 20 μg/mL | [143] |
| isobonducellin (123) | homoisoflavonoid | microsomes | 41.0 | PCA at 20 μg/mL | [143] |
| isobonducellin (123) | homoisoflavonoid | SK-BR-3 cells | 58.4 | PCA at 50 μM | [143] |
| 4'-dehydroxycabenegrin A (124) | pterocarpan | microsomes | 50.9 | PCA at 20 μg/mL | [143] |
| (−)-hemileiocarpin (125) | pterocarpan | microsomes | 69.8 | PCA at 20 μg/mL | [143] |
| 2-hydroxyleiocarpin (126) | pterocarpan | microsomes | 73.3 | PCA at 20 μg/mL | [143] |
| leiocarpin (127) | pterocarpan | microsomes | 83.9 | PCA at 20 μg/mL | [143] |
| medicarpin (128) | pterocarpan | microsomes | >50 | μM IC50 | [123] |
| amorphigenin (129) | rotenoid | microsomes | 83.7 | PCA at 20 μg/mL | [143] |
| amorphigenin glucoside (130) | rotenoid | microsomes | 83.0 | PCA at 20 μg/mL | [143] |
| dalbinol (131) | rotenoid | microsomes | 86.5 | PCA at 20 μg/mL | [143] |
| rotenone (132) | rotenoid | H295R adrenocortical carcinoma cells | 0.30 | μM IC50 | [127] |
From the literature, ten alkaloids have been reported as being tested for aromatase inhibition (Table 10, Fig. 11). Five of these alkaloids were isolated from Nicotiana tabacum L. [113, 150], with the others from Hydrastis canadensis L. (goldenseal), and Piper L. sp. [143]. None were found to inhibit aromatase.
Table 10
Previous literature reports of alkaloids tested for aromatase inhibition
| Compound Name | Assay Type | Activity | Ref.(s) | |
|---|---|---|---|---|
| anabasine (133) | microsomes | 6600 | μM IC50 | [113] |
| berberine (134) | microsomes | 87.5 | PCA at 20 μg/mL | [143] |
| cotinine (135) | microsomes | none | [113] | |
| β-hydrastine (136) | microsomes | 95.6 | PCA at 20 μg/mL | [143] |
| N-(4-hydroxy-undecanoyl)anabasine (137) | microsomes | 30 | μM IC50 | [150] |
| nicotine (138) | microsomes | 4 | cigarette equiv. | [113] |
| nicotine (138) | microsomes | 26000 | μM IC50 | [113] |
| N-n-octanoylnornicotine (139) | microsomes | 360 | μM IC50 | [113] |
| N-n-octanoylnornicotine (139) | microsomes | 360 | μM IC50 | [150] |
| 8-oxotetrahydrothalifendine (140) | microsomes | 96.0 | PCA at 20 μg/mL | [143] |
| 1-[1-oxo-5(8,9-methylenedioxyphenyl)-2E,4Z-pentadienyl]-piperidine (141) | microsomes | 97.7 | PCA at 20 μg/mL | [143] |
| piperine (142) | microsomes | 100.6 | PCA at 20 μg/mL | [143] |
Fifteen fatty acids have been tested for aromatase inhibition (Table 11, Fig. 12). Using the categories delineated above, one of the fatty acids, (10E,12Z)-9-oxo-10,12-octadecadienoic acid (154) isolated from Urtica dioica L. (stinging nettle) showed moderate aromatase inhibitory activity [151]. Two other fatty acids, (10E,12Z)-9-hydroxy-10,12-octadecadienoic acid (149) and docosapentaenoic acid (146) [152], showed weak aromatase inhibitory activity in microsomal testing [151]. However, though several unsaturated fatty acids exhibited strong aromatase inhibitiory activity during initial screening they were found to be inactive in cellular aromatase testing [152]. In bioassay-guided studies on natural product extracts for aromatase inhibition activity, fatty acids may be regarded as “interfering” substances, since they are active in noncellular, enzyme-based aromatase assays but do not inhibit aromatase in secondary cellular testing [152].
Table 11
Previous literature reports of natural product fatty acids tested for aromatase inhibition
| Compound Name | Assay Type | Activity | Ref.(s) | |
|---|---|---|---|---|
| arachidonic acid (143) | microsomes | 11.5 | PCA at 20 μg/mL | [152] |
| arachidonic acid (143) | microsomes | 28.2 | μM IC50 | [152] |
| arachidonic acid (143) | SK-BR-3 cells | 147.2 | PCA at 100 μM | [152] |
| azelaic acid (144) | microsomes | none | [113] | |
| docosahexaenoic acid (145) | microsomes | 12.4 | PCA at 20 μg/mL | [152] |
| docosahexaenoic acid (145) | microsomes | 33.2 | μM IC50 | [152] |
| docosahexaenoic acid (145) | SK-BR-3 cells | 98.2 | PCA at 100 μM | [152] |
| docosapentaenoic acid (146) | microsomes | 15.7 | PCA at 20 μg/mL | [152] |
| docosapentaenoic acid (146) | microsomes | 16.8 | μM IC50 | [152] |
| docosapentaenoic acid (146) | SK-BR-3 cells | 94.4 | PCA at 100 μM | [152] |
| eicosapentaenoic acid (147) | microsomes | 30.2 | PCA at 20 μg/mL | [152] |
| eicosapentaenoic acid (147) | microsomes | 53.2 | μM IC50 | [152] |
| eicosapentaenoic acid (147) | SK-BR-3 cells | 137.6 | PCA at 100 μM | [152] |
| (9Z,11E)-12-hydroxy-9,11-octadecadienoic acid (148) | microsomes | 15.9 | %inhib. at 313.0 μM | [155] |
| (10E,12Z)-9-hydroxy-10,12-octadecadienoic acid (149) | microsomes | 84 | % inhib. | [151] |
| linoleic acid (150) | microsomes | 22.5 | PCA at 20 μg/mL | [152] |
| linoleic acid (150) | microsomes | 7.4 | PCA at 20 μg/mL | [108] |
| linoleic acid (150) | microsomes | 48.0 | μM IC50 | [152] |
| linoleic acid (150) | SK-BR-3 cells | 147.6 | PCA at 100 μM | [152] |
| α-linolenic acid (151) | microsomes | 49.5 | PCA at 20 μg/mL | [152] |
| α-linolenic acid (151) | microsomes | 44.2 | μM IC50 | [152] |
| α-linolenic acid (151) | SK-BR-3 cells | 92.8 | PCA at 100 μM | [152] |
| myristic acid (152) | microsomes | 66.7 | PCA at 20 μg/mL | [152] |
| oleic acid (153) | microsomes | 19.5 | PCA at 20 μg/mL | [152] |
| oleic acid (153) | microsomes | 32.7 | μM IC50 | [152] |
| oleic acid (153) | SK-BR-3 cells | 99.3 | PCA at 100 μM | [152] |
| (10E,12Z)-9-oxo-10,12-octadecadienoic acid (154) | microsomes | 95 | % inhib. | [151] |
| palmitic acid (155) | microsomes | 83.2 | PCA at 20 μg/mL | [152] |
| pentadecanoic acid (156) | microsomes | 76.2 | PCA at 20 μg/mL | [152] |
| stearic acid (157) | microsomes | 89.4 | PCA at 20 μg/mL | [152] |
In previous literature reports, eighteen lignans were evaluated for aromatase inhibition (Table 12, Fig. 13). The mammalian lignans enterodiol (166) and enterolactone (167) were each tested three times, as was nordihydroguaiaretic acid (172). Enterolactone (167) was moderately active in microsomes and strongly active using Arom+HEK 293 cells [153]. Nordihydroguaiaretic acid (172) was weakly active in micromal testing [145], although this compound was also found to be inactive in microsomes by another group [154]. Of the other lignans tested, 4,4'-dihydroxyenterolactone (164) was moderately active and 4,4'-enterolactone (165) was weakly active in microsomal aromatase testing [145]. All other lignans tested were inactive, although nectandrin B (171), isolated from Myristica argentea Warb. [154], and secoisolariciresinol (173) isolated from Urtica dioica L. (stinging nettle) [155] were both previously reported as active compounds.
Table 12
Previous literature reports of natural product lignans tested for aromatase inhibition
| Compound Name | Assay Type | Activity | Ref.(s) | |
|---|---|---|---|---|
| erythro-austrobailignan-6 (158) | microsomes (modified) | 0 | % inhib. at 50 μM | [154] |
| threo-austrobailignan-5 (159) | microsomes (modified) | 0 | % inhib. at 50 μM | [154] |
| dehydrodesoxypodophyllotoxin (160) | microsomes | 96.0 | PCA at 20 μg/mL | [143] |
| dehydropodophyllotoxin (161) | microsomes | 88.1 | PCA at 20 μg/mL | [143] |
| 3'-demethoxymatairesinola (162) | microsomes | 37 | μM IC50 | [145] |
| meso-dihydroguaiaretic acid (163) | microsomes (modified) | 15.1 | % inhib. at 50 μM | [154] |
| 4,4'-dihydroxyenterolactone (164) | microsomes | 6 | μM IC50 | [145] |
| 4,4'-enterolactone (165) | microsomes | 15 | μM IC50 | [145] |
| enterodiol (166) | microsomes | 30 | μM IC50 | [145] |
| enterodiol (166) | Arom+HEK 293 cells | >10 | μM IC50 | [153] |
| enterodiol (166) | preadipose cells | >100 | μM IC50 | [134] |
| enterolactone (167) | Arom+HEK 293 cells | 8.90 | μM IC50 | [153] |
| enterolactone (167) | microsomes | 14 | μM IC50 | [145] |
| enterolactone (167) | preadipose cells | 74 | μM IC50 | [134] |
| epiaschantin (168) | microsomes | 76.7 | PCA at 20 μg/mL | [143] |
| (−)-hernolactone (169) | microsomes | 73.5 | PCA at 20 μg/mL | [143] |
| matairesinola (170) | Arom+HEK 293 cells | >10 | μM IC50 | [153] |
| nectandrin B (171) | microsomes (modified) | 30 | % inhib. at 50 μM | [154] |
| nordihydroguaiaretic acida (172) | microsomes | 11 | μM IC50 | [145] |
| nordihydroguaiaretic acida (172) | microsomes (modified) | 42 | % inhib. at 50 μM | [154] |
| nordihydroguaiaretic acida (172) | nd | 68.70 | μM IC50 | [149] |
| secoisolariciresinol (173) | microsomes | 10.9 | % inhib. at 409.0 μM | [155] |
| secoisolariciresinol (173) | Arom+HEK 293 cells | >10 | μM IC50 | [153] |
| (−)-syringaresinol (174) | microsomes | 60.2 | PCA at 20 μg/mL | [143] |
| (−)-yatein (175) | microsomes | 74.2 | PCA at 20 μg/mL | [143] |
nd = no data
From the literature, nineteen natural product peptides were tested for aromatase inhibition (Table 13, Fig. 14). Sixteen peptides were isolated from an unidentified soil bacterium and were similar in structure, varying only in two side chains and two residues [156]. Most of these peptides from bacteria were inactive in microsomes, with SNA-60-367-6 (186) and -11 (190) being weakly active [156]. No cellular testing was done on these compounds. N-Benzoyl-L-phenylalanine methyl ester (177), isolated from Brassaiopsis glomerulata L., was found to be weakly active in SK-BR-3 cells [108].
Table 13
Previous literature reports of natural product peptides tested for aromatase inhibition
| Compound Name | Assay Type | Activity | Ref.(s) | |
|---|---|---|---|---|
| N-acetyl-L-phenylalaninyl-N-benzoyl-L-phenylalaninate (176) | microsomes | 83.0 | PCA at 20 μg/mL | [108] |
| N-acetyl-L-phenylalaninyl-N-benzoyl-L-phenylalaninate (176) | SK-BR-3 cells | 114.1 | PCA at 50 μM | [108] |
| N-benzoyl-L-phenylalanine methyl ester (177) | microsomes | 94.3 | PCA at 20 μg/mL | [108] |
| N-benzoyl-L-phenylalanine methyl ester (177) | SK-BR-3 cells | 33.3 | PCA at 50 μM | [108] |
| N-benzoyl-L-phenylalaninyl-N-benzoyl-L-phenylalaninate (178) | microsomes | 94.2 | PCA at 20 μg/mL | [108] |
| N-benzoyl-L-phenylalaninyl-N-benzoyl-L-phenylalaninate (178) | SK-BR-3 cells | 121.8 | PCA at 50 μM | [108] |
| SNA-60-367-2 (179) | microsomes | 60 | % inhib. at 100 μg/mL | [156] |
| SNA-60-367-2 (179) | microsomes | 63 | μM IC50 | [156] |
| SNA-60-367-4 (180) | microsomes | 65 | % inhib. at 100 μg/mL | [156] |
| SNA-60-367-5 (181) | microsomes | 63 | % inhib. at 100 μg/mL | [156] |
| SNA-60-367-6 (182) | microsomes | 74 | % inhib. at 100 μg/mL | [156] |
| SNA-60-367-8 (183) | microsomes | 61 | % inhib. at 100 μg/mL | [156] |
| SNA-60-367-9 (184) | microsomes | 55 | % inhib. at 100 μg/mL | [156] |
| SNA-60-367-10 (185) | microsomes | 68 | % inhib. at 100 μg/mL | [156] |
| SNA-60-367-10 (185) | microsomes | 42 | μM IC50 | [156] |
| SNA-60-367-11 (186) | microsomes | 72 | % inhib. at 100 μg/mL | [156] |
| SNA-60-367-12 (187) | microsomes | 60 | % inhib. at 100 μg/mL | [156] |
| SNA-60-367-13 (188) | microsomes | 50 | % inhib. at 100 μg/mL | [156] |
| SNA-60-367-13 (188) | microsomes | 66 | μM IC50 | [156] |
| SNA-60-367-14 (189) | microsomes | 31 | % inhib. at 100 μg/mL | [156] |
| SNA-60-367-17 (190) | microsomes | 48 | % inhib. at 100 μg/mL | [156] |
| SNA-60-367-18 (191) | microsomes | 49 | % inhib. at 100 μg/mL | [156] |
| SNA-60-367-19 (192) | microsomes | 49 | % inhib. at 100 μg/mL | [156] |
| SNA-60-367-21 (193) | microsomes | 36 | % inhib. at 100 μg/mL | [156] |
| SNA-60-367-23 (194) | microsomes | 32 | % inhib. at 100 μg/mL | [156] |
A total of 36 terpenoids have been tested for aromatase inhibition, including ten diterpenoids, ten steroids, seven triterpenoids, five isoprenoids, two sesquiterpenoids, and two withanolides (Table 14, Fig. 15). Of the terpenoids tested, diterpenoids and steroids have been tested most often but were only found to be weakly inhibitory or inactive. The most active of the diterpenoids using recombinant yeast microsomes was the ring C-aromatized compound, standishinal (203), isolated from Thuja standishii Carrière [157]. Inflexin (198), an ent-kaurane diterpenoid, isolated from Isodon excisus Kudo var. coreanus, was also active in micromal aromatase testing [110]. These two diterpenes show little similarity, making structural comparisons within the diterpenoid class difficult. Ten steroids isolated from Aglaia ponapensis Kaneh. [158], Albizia falcataria (L.) Fosberg, and Brassaiopsis glomerulata (Blume) Regel [108] were found to be inactive in microsomal aromatase testing.
Table 14
Previous literature reports of natural product terpenoids tested for aromatase inhibition (listed alphabetically by compound class)
| Compound Name | Compound Class | Assay Type | Activity | Ref.(s) | |
|---|---|---|---|---|---|
| trans-communic acid (195) | diterpenoid | recombinant yeast microsomes | 0 | % inhib. at 1 μM | [157] |
| 12S-hydroxylabda-8(17),13(15), 14-trien-19-oic acid (196) | diterpenoid | recombinant yeast microsomes | 0 | % inhib. at 1 μM | [157] |
| 12-hydroxy-6,7-seco-abieta-8,11,13-triene-6,7-dial (197) | diterpenoid | recombinant yeast microsomes | 0 | % inhib. at 1 μM | [157] |
| inflexin (198) | diterpenoid | microsomes | 9.2 | μg/mL IC50 | [110] |
| labda-8(17),13-dien-12R,15-olid-19-oic acid (199) | diterpenoid | recombinant yeast microsomes | 7.2 | % inhib. at 1 μM | [157] |
| 12-methoxyabieta-8,11,13-trien-11-ol (200) | diterpenoid | recombinant yeast microsomes | 0 | % inhib. at 1 μM | [157] |
| 13-oxo-15,16-dinorlabda-8(17),11E-dien-19-oic acid (201) | diterpenoid | recombinant yeast microsomes | 0 | % inhib. at 1 μM | [157] |
| 14-oxo-15-norlabda-8(17),12E-dien-19-oic acid (202) | diterpenoid | recombinant yeast microsomes | 0 | % inhib. at 1 μM | [157] |
| standishinal (203) | diterpenoid | recombinant yeast microsomes | 50.2 | % inhib. at 1 μM | [157] |
| totarol (204) | diterpenoid | recombinant yeast microsomes | 0 | % inhib. at 1 μM | [157] |
| (−)-dehydrololiolide (205) | isoprenoid | microsomes | 91.5 | PCA at 20 μg/mL | [108] |
| (−)-dehydrololiolide (205) | isoprenoid | SK-BR-3 cells | 21.8 | PCA at 50 μM | [108] |
| 4-[(1E)-3-hydroxy-1-butenyl]-3,5,5-trimethyl-(4R)-2-cyclohexen-1-one (206) | isoprenoid | microsomes | 93.5 | PCA at 20 μg/mL | [143] |
| 4-(4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]hept-1-yl)-3 E-buten-2-one (207) | isoprenoid | microsomes | 62.3 | PCA at 20 μg/mL | [143] |
| loliolide (208) | isoprenoid | microsomes | 84.6 | PCA at 20 μg/mL | [143] |
| menthol (209) | isoprenoid | microsomes | none | [113] | |
| 10-epi-8-deoxycumambrin B (210) | sesquiterpenoid | microsomes | 7.0 | μM IC50 | [161] |
| 11βH,13-dihydro-10-epi-8-deoxycumambrin (211) | sesquiterpenoid | microsomes | 2.0 | μM IC50 | [161] |
| 11βH,13-dihydro-10-epi-8-deoxycumambrin (211) | sesquiterpenoid | JEG-3 choriocarcino ma cells | 10 | μM IC50 | [161] |
| 2β,3β-dihydroxy-5-preg-17(20)-(E)-en-16-one (212) | steroid | microsomes | 81.7 | PCA at 20 μg/mL | [143] |
| 2β,3β-dihydroxy-5-preg-17(20)-(Z)-en-16-one (213) | steroid | microsomes | 77.4 | PCA at 20 μg/mL | [143] |
| 6β-hydroxystigmasta-4-en-3-one (214) | steroid | microsomes | 94.2 | PCA at 20 μg/mL | [108] |
| 6β-hydroxystigmasta-4-en-3-one (214) | steroid | SK-BR-3 cells | 46.3 | PCA at 50 μM | [108] |
| 7β-hydroxy-4,22-stigmastadien-3-one (215) | steroid | microsomes | 79.8 | PCA at 20 μg/mL | [108] |
| 7β-hydroxy-4,22-stigmastadien-3-one (215) | steroid | SK-BR-3 cells | 127.6 | PCA at 50 μM | [108] |
| spinasterol (216) | steroid | microsomes | 96.9 | PCA at 20 μg/mL | [108] |
| spinasterol (216) | steroid | SK-BR-3 cells | 103.5 | PCA at 50 μM | [108] |
| spinasterol glucoside (217) | steroid | microsomes | 93.1 | PCA at 20 μg/mL | [143] |
| spinasterone (218) | steroid | microsomes | 91.9 | PCA at 20 μg/mL | [108] |
| spinasterone (218) | steroid | SK-BR-3 cells | 98.6 | PCA at 50 μM | [108] |
| stigmasterol (219) | steroid | microsomes | 99.6 | PCA at 20 μg/mL | [108] |
| stigmasterol (219) | steroid | SK-BR-3 cells | 114.6 | PCA at 50 μM | [108] |
| (E)-volkendousin (220) | steroid | microsomes | 73.8 | PCA at 20 μg/mL | [143] |
| (Z)-volkendousin (221) | steroid | microsomes | 52.8 | PCA at 20 μg/mL | [143] |
| aglaiaglabretol A (222) | triterpenoid | microsomes | 97.4 | PCA at 20 μg/mL | [143] |
| aglaiaglabretol B (223) | triterpenoid | microsomes | 49.4 | PCA at 20 μg/mL | [143] |
| aglaiaglabretol B (223) | triterpenoid | SK-BR-3 cells | 16.5 | PCA at 50 μM | [143] |
| betulinic acid (224) | triterpenoid | microsomes | 89.5 | PCA at 20 μg/mL | [143] |
| maslinic acid (225) | triterpenoid | microsomes | 56.5 | PCA at 20 μg/mL | [143] |
| oleanolic acid (226) | triterpenoid | microsomes | 83.5 | PCA at 20 μg/mL | [108] |
| oleanolic acid (226) | triterpenoid | microsomes | 12.4 | % inhib. at 40.7 μM | [155] |
| oleanolic acid (226) | triterpenoid | SK-BR-3 cells | 93.5 | PCA at 50 μM | [108] |
| ursolic acid (227) | triterpenoid | microsomes | 103.1 | PCA at 20 μg/mL | [143] |
| ursolic acid (227) | triterpenoid | microsomes | 30.4 | % inhib. at 81.5 μM | [155] |
| ursolic acid (227) | triterpenoid | microsomes | 14.0 | μg/mL IC50 | [110] |
| ursolic acid (227) | triterpenoids | microsomes | 32 | μM IC50 | [193] |
| ursolic acid 3-O-acetate (228) | triterpenoid | microsomes | 42.7 | μg/mL IC50 | [110] |
| ixocarpalactone A (229) | withanolide | microsomes | 105.6 | PCA at 20 μg/mL | [143] |
| ixocarpalactone B (230) | withanolide | microsomes | 106.7 | PCA at 20 μg/mL | [143] |
Of the seven triterpenoids ursolic acid (227), isolated from Isodon excisus Kudo var. coreanus [110] and Urtica dioica L. [155], was tested in microsomes and found to be moderately inhibitory once [110], but otherwise inactive. Another of the triterpenoids tested, aglaiaglabretol B (223) isolated from Aglaia crassinervia Kurz ex Hiern [159], was moderately active against SK-BR-3 cells [143]. However, aglaiaglabretol B (223) was also found to be cytotoxic during previous work [159], limiting the potential use of this compound as an aromatase inhibitor.
Of the five isoprenoids (−)-dehydrololiolide (205), isolated from Brassaiopsis glomerulata (Blume) Regel, moderately inhibited aromatase in SK-BR-3 cells [108]. The other four isoprenoids were inactive.
A sesquiterpene lactone, 11βH,13-dihydro-10-epi-8-deoxycumambrin (211), isolated from Stevia yaconensis Hieron. var. subeglandulosa [160], was found to be strongly active using microsomal aromatase testing [161]. Though the other sesquiterpene lactone 10-epi-8-deoxycumambrin B (210) was found to be moderately active in microsomes it was found to be cytotoxic in further testing [161]. The former was moderately active as an aromatase inhibitor in JEG-3 choriocarcinoma cells and was not cytotoxic [161].
The two withanolides, isolated from Physalis philadelphica Lam. (tomatillo, an edible fruit similar to tomato often used in salsa) [162], were found to be inactive against aromatase in microsome testing [143].
Sixteen xanthones were tested for aromatase inhibition in microsomes (Table 15, Fig. 16). Twelve xanthones were isolated from Garcinia mangostana L. (mangosteen) [163]. γ-Mangostin (276) and garcinone D (270), were found to be strongly active in microsomes and α-mangostin (275) and garcinone E (271) were found to be moderately active. The other xanthones from G. mangostana L. were inactive. Four xanthones were isolated from a marine fungus, Monodictys putredinis [164], and were found to be inactive in microsomal testing.
Table 15
Previous literature reports of natural product xanthones tested for aromatase inhibition
| Compound Name | Assay Type | Activity | Ref.(s) | |
|---|---|---|---|---|
| cudraxanthone G (231) | microsomes | 57.8 | PCA at 20 μg/mL | [109] |
| 8-deoxygartanin (232) | microsomes | 82.6 | PCA at 20 μg/mL | [109] |
| garcinone D (233) | microsomes | 10.0 | PCA at 20 μg/mL | [109] |
| garcinone D (233) | microsomes | 5.16 | μM IC50 | [109] |
| garcinone D (233) | SK-BR-3 cells | 50.7 | PCA at 50 μM | [109] |
| garcinone E (234) | microsomes | 23.9 | PCA at 20 μg/mL | [109] |
| garcinone E (234) | microsomes | 25.14 | μM IC50 | [109] |
| garcinone E (234) | SK-BR-3 cells | 32.3 | PCA at 50 μM | [109] |
| gartanin (235) | microsomes | 75.9 | PCA at 20 μg/mL | [109] |
| 8-hydroxycudraxanthone G (236) | microsomes | 55.1 | PCA at 20 μg/mL | [109] |
| 1-isomangostin (237) | microsomes | 52.6 | PCA at 20 μg/mL | [109] |
| α-mangostin (238) | microsomes | 22.2 | PCA at 20 μg/mL | [109] |
| α-mangostin (238) | microsomes | 20.66 | μM IC50 | [109] |
| α-mangostin (238) | SK-BR-3 cells | 59.4 | PCA at 50 μM | [109] |
| γ-mangostin (239) | microsomes | 4.7 | PCA at 20 μg/mL | [109] |
| γ-mangostin (239) | microsomes | 6.88 | μM IC50 | [109] |
| γ-mangostin (239) | SK-BR-3 cells | −0.5 | PCA at 50 μM | [109] |
| γ-mangostin (239) | SK-BR-3 cells | 4.97 | μM IC50 | [109] |
| mangostinone (240) | microsomes | 78.8 | PCA at 20 μg/mL | [109] |
| monodictysin A (241) | DBF enzyme1 | 32 | % inhib. at 50 μM | [164] |
| monodictysin B (242) | DBF enzyme1 | 9 | % inhib. at 50 μM | [164] |
| monodictysin C (243) | DBF enzyme1 | 28.3 | μM IC50 | [164] |
| monodictyxanthone (244) | DBF enzyme1 | 37 | % inhib. at 50 μM | [164] |
| smeathxanthone A (245) | microsomes | 80.8 | PCA at 20 μg/mL | [109] |
| tovophylline A (246) | microsomes | 74.7 | PCA at 20 μg/mL | [109] |
There have been 43 miscellaneous natural product compounds tested for aromatase inhibition in the literature (Table 16, Fig. 17). Fourteen benzenoids were tested, with TAN-931 (269) isolated from the bacterium Penicillium funiculosum No. 8974 [165], being weakly active in microsomes. TAN-931 (269) was further tested in vivo using Sprague-Dawley rats and was found to reduce estradiol levels presumably, although not definitively, through aromatase inhibition [165]. All other benzenoids were inactive.
Structures of miscellaneous natural products (not previously mentioned) tested for aromatase inhibition.
Table 16
Previous literature reports of miscellaneous natural products (not previously mentioned) tested for aromatase (listed alphabetically by compound class)
| Compound Name | Compound Class | Assay Type | Activity | Ref.(s) | |
|---|---|---|---|---|---|
| 14-octacosanol (247) | alkanol | microsomes | 24.3 | % inhib. at 29.6 μM | [155] |
| alizarin-1-methyl ether (248) | anthraquinone | microsomes | 82.5 | PCA at 20 μg/mL | [143] |
| benzanthraquinone I (249) | anthraquinone | 94 | % inhib. at 25 μM | [168] | |
| 3-hydroxy-2-(hydroxymethyl)-anthraquinone (250) | anthraquinone | microsomes | 82.1 | PCA at 20 μg/mL | [143] |
| morindone-5-methyl ether (251) | anthraquinone | microsomes | 92.5 | PCA at 20 μg/mL | [143] |
| rubiadin-1-methyl ether (252) | anthraquinone | microsomes | 99.0 | PCA at 20 μg/mL | [143] |
| soranjidol (253) | anthraquinone | microsomes | 96.2 | PCA at 20 μg/mL | [143] |
| 1,5,7-trihydroxy-2-methyl-anthraquinone (254) | anthraquinone | microsomes | 50.5 | PCA at 20 μg/mL | [143] |
| benzo[a]pyrene (255) | aromatic hydrocarbon | microsomes | none | [113] | |
| benzoic acid (256) | benzenoid | microsomes | none | [113] | |
| broussonin A (257) | benzenoid | microsomes | 30.0 | μM IC50 | [135] |
| trans-cinnamic acid (258) | benzenoid | microsomes | none | [113] | |
| O-desmethylangolensin (259) | benzenoid | microsomes | 160 | μM IC50 | [145] |
| 3,4-dihydroxybenzoic acid (260) | benzenoid | microsomes | none | [113] | |
| 3,4-dihydroxycinnamic acid (261) | benzenoid | microsomes | none | [113] | |
| 4-hydroxybenzoic acid (262) | benzenoid | microsomes | 90.8 | PCA at 20 μg/mL | [108] |
| 4-hydroxybenzoic acid (262) | benzenoid | microsomes | none | [113] | |
| 4-hydroxybenzoic acid (262) | benzenoid | SK-BR-3 cells | 84.3 | PCA at 50 μM | [108] |
| 4-hydroxycinnamic acid (263) | benzenoid | microsomes | none | [113] | |
| MF-1 (264) | benzenoid | microsomes | 30 | μM IC50 | [145] |
| MF-2 (265) | benzenoid | microsomes | 100 | μM IC50 | [145] |
| monodictyphenone (266) | benzenoid | DBF enzyme1 | 25 | % inhib. at 50 μM | [164] |
| oleuropein (267) | benzenoid | microsomes | 27 | μM IC50 | [136] |
| phenylacetic acid (268) | benzenoid | microsomes | none | [113] | |
| TAN-931 (269) | benzenoid | microsomes | 17.2 | μM IC50 | [165] |
| TAN-931 (269) | benzenoid | in vivo Sprague-Dawley rats | reduced | estradiol levels | [165] |
| demethylmoracin I (270) | benzofuran | microsomes | 31.1 | μM IC50 | [135] |
| moracin N (271) | benzofuran | microsomes | 31.1 | μM IC50 | [135] |
| chlorophyllide a (272) | chlorophyll | microsomes | 80.3 | PCA at 20 μg/mL | [143] |
| esculetin (273) | coumarin | microsomes | >640 | μM IC50 | [136] |
| isoscopoletin (274) | coumarin | microsomes | >640 | μM IC50 | [136] |
| 8-methoxypsoralen (275) | coumarin | in vivo female Wistar rats | decreased | aromatase protein | [194] |
| scoparon (276) | coumarin | microsomes | >640 | μM IC50 | [136] |
| scopoletin (277) | coumarin | microsomes | >640 | μM IC50 | [136] |
| curcumin (278) | diarylheptanoid | microsomes | none | [149] | |
| aculeatin A (279) | dioxadispiroketal | microsomes | 66.8 | PCA at 20 μg/mL | [143] |
| aculeatin B (280) | dioxadispiroketal | microsomes | 77.2 | PCA at 20 μg/mL | [143] |
| albanol A (281) | miscellaneous | microsomes | 7.5 | μM IC50 | [135] |
| FR 901537 (282) | miscellaneous | nd | nd | [195] | |
| sodium butyrate (283) | miscellaneous | breast adipose fibroblast cells | decreased | promoter specific aromatase mRNA | [196] |
| zearalenone (284) | miscellaneous | granulosa-luteal cells | inhibited | at 10 μmol/L for 24h | [129] |
| limnophilaspiroketone (285) | spiroketone | microsomes | 106.2 | PCA at 20 μg/mL | [143] |
| resveratrol (286) | stilbenoid | microsomes | 51.9 | PCA at 20 μg/mL | [143] |
| resveratrol (286) | stilbenoid | microsomes | 12.8 | μM IC50 | [136] |
| resveratrol (286) | stilbenoid | nd | ~115 | % inhib. at 100 μM | [107] |
| ellagic acid (287) | tannin | microsomes | 99.5 | PCA at 20 μg/mL | [143] |
| oenothein A (288) | tannin | microsomes | 70 | % inhib. at 50 μM | [130] |
| oenothein A (288) | tannin | nd | nd | [197] | |
| oenothein B (289) | tannin | microsomes | 33 | % inhib. at 50 μM | [130] |
| oenothein B (289) | tannin | nd | nd | [197] | |
Seven anthraquinones have been tested, six of which were isolated from Morinda citrifolia L. (noni), a widely used botanical dietary supplement [166, 167]. None of the anthraquinones isolated from M. citrifolia was found to be active in microsomal aromatase testing. Benzanthraquinone I (249), isolated from the bacteria Streptomyces S-11106, exhibited strong aromatase inhibitory activity in microsomes [168].
The stilbenoid, resveratrol (286), isolated from Vitis L. sp. [107], was reported to strongly inhibit aromatase in microsomes [107], to moderately inhibit aromatase in another microsomal test [136], and to be inactive when tested a third time [143]. One of the miscellaneous compounds, albanol A (281) isolated from Broussonetia papyrifera Vent. [135], was found to moderately inhibit aromatase in microsomes. All other miscellaneous compounds, including all alkanols, aromatic hydrocarbons, benzofurans, chlorophylls, diarylheptanoids, dioxadispiroketals, spiroketones, and tannins, were found to be inactive against aromatase.
CONCLUSIONS
Numerous natural product extracts, from plant, fungal, and microbial terrestrial and marine sources, have been evaluated for aromatase inhibition using various noncellular, cell-based, and in vivo assays. Some of the more active extracts included those of Agaricus bisporus (Lange) Imbach (white button mushrooms) [115] and Vitis L. sp. (grape and/or wine) [86, 106, 107], among others. Some aromatase activity-guided fractionation has been performed on Vitis sp. extracts, resulting in the isolation of various procyanidin dimers that have yet to be fully characterized [86]. Interestingly, several types of extracts and partitions of A. bisporus and a sample of Vitis sp. (grape) were subsequently tested for their ability to inhibit aromatase in microsomes and found to be inactive [143]. Several factors could be involved in the discrepancies between the literature results, including variations in the species collected, timing of collections, purity of materials extracted, preparation of extracts, and assay methodology.
Several other extracts were determined to inhibit aromatase in microsomes including from Brassaiopsis glomerulata (Blume) Regel [108] and Garcinia mangostana L. (mangosteen) [109], with both of these species having undergone activity-guided purification resulting in the isolation of compounds with AI activity. Extracts of several cycads were also found to be potent AIs [104] but, to date, their bioassay-guided fractionation has not been performed. Another active extract that has not undergone fractionation is Euonymus alatus [111]. Active compounds isolated from these extracts may provide potent AIs and possible leads for further development.
Nearly 300 natural product compounds have been evaluated for their ability to inhibit aromatase, in noncellular, cell-based, and in vivo aromatase inhibition assays. Flavonoids have been tested most frequently and generally found to be the most active class of natural product AI compounds. Some of the more active flavonoids included apigenin (8), chrysin (11), 7-hydroxyflavone (26), isolicoflavonol (27), (2S)-abyssinone II (45), (2S)-2',4'-dihydroxy-2”-(1-hydroxy-1-methylethyl)dihydrofuro[2,3-h]flavanone (49), eriodictyol (50), 8-prenylnaringenin (62), 3'-[γ-hydroxymethyl-(E)-γ-methylallyl]-2,4,2',4'-tetrahydroxychalcone 11'-O-coumarate (75), isoliquiritigenin (77), and rotenone (132). Other very active AI compounds included the xanthone, γ-mangostin (239), the sesquiterpene lactone, 11βH,13-dihydro-10-epi-8-deoxycumambrin (211), and the anthraquinone, benzanthraquinone I (249).
Since natural product drug discovery efforts frequently utilize non-cellular screening assays, several of the compounds reported to be active in non-cellular assays should be avoided by future AI drug discovery endeavors. This is exemplified by the unsaturated fatty acids, which are commonly found in natural product extracts and have been shown to interfere with non-cellular AI assays [152]. Several flavonoids have also been found to be active in non-cellular screening and inactive in cell-based assays. In natural product AI screening efforts it is recommended that extracts active in non-cellular bioassays be dereplicated for the presence of known aromatase inhibitors prior to expensive and time-consuming bioassay-guided fractionation.
All of the most active compounds were of the flavonoid or xanthone compound classes, with the exception of the active sesquiterpene lactone and the active anthraquinone. The ability of flavonoids to inhibit aromatase has been well established [169, 170] and some flavonoids have continued into in vivo studies with various results [125, 148]. Interestingly, Saarinen et al. [125] have shown that apigenin (8), chrysin (11), and naringenin (59) were all inactive using an in vivo AI mouse model. The AI activity of flavonoids needs further in vivo testing to substantiate the extensive and potent in vitro results. Various AI mouse models are currently available or in development, including a transgenic model that overexpresses aromatase [171], an aromatase-knockout mouse model [172], and a MCF-7 xenograft model [173].
Several natural product compounds have already undergone synthetic modifications to further enhance AI activity. Two separate syntheses have been performed on the strongly active flavone (2S)-abyssinone II (45) [174, 175] and several analogues have been found to be more active than the natural compound. Synthesis of 7,8-benzoflavanones has provided several leads with potent AI activity [176]. Ursolic acid (227) derivatives were synthesized with resulting compounds having lower activity than the natural product [177]. The diterpenoid, standishinal (203), and several synthetic derivatives were subjected to AI testing with the most active compounds having a cis-configuration on the A/B ring [178]. Synthetic xanthones have only recently been tested for their ability to inhibit aromatase [48, 179, 180] with extremely potent AI activity in the nanomolar range. However, very few natural product or synthetic compounds have undergone extensive evaluation using additional in vitro or in vivo and preclinical models.
This review highlights several compound classes that may act as aromatase inhibitors (e.g., flavones, flavanones, chalcones, and xanthones) and other structural classes that are less active. These scaffolds may be utilized to direct synthetic modification of natural product scaffolds to enhance aromatase inhibition. New natural products or natural product analogues that inhibit aromatase may be clinically useful for treating postmenopausal breast cancer. Aromatase inhibitors may also act as chemopreventive agents for preventing secondary recurrence of breast cancer. Furthermore, AIs from edible plant materials may eventually be appropriate for primary prevention of breast cancer in postmenopausal women (e.g., lower toxicity due to history of human consumption). Botanical dietary supplements or foods that are ingested regularly and act as AIs may have a role in breast cancer chemoprevention or chemotherapy for postmenopausal women.
ACKNOWLEDGEMENTS
Financial support was obtained through a University Fellowship and a Dean's Scholar Award from the Graduate College of the University of Illinois at Chicago, awarded to M.J.B. Other support was provided by NIH grant R01 CA73698 (P.I., R.W.B.), The Ohio State University Comprehensive Cancer Center (OSUCCC) Breast Cancer Research Fund (to R.W.B.) and the OSUCCC Molecular Carcinogenesis and Chemoprevention Program (to A.D.K.).